CLINICAL AND PATHOLOGIC SIGNIFICANCE OF INTEGRIN α6β4 EXPRESSION IN HUMAN MALIGNANCIES by Stewart, Rachel L.
University of Kentucky 
UKnowledge 
Theses and Dissertations--Clinical and 
Translational Science Behavioral Science 
2015 
CLINICAL AND PATHOLOGIC SIGNIFICANCE OF INTEGRIN α6β4 
EXPRESSION IN HUMAN MALIGNANCIES 
Rachel L. Stewart 
University of Kentucky, rachel.stewart@uky.edu 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Stewart, Rachel L., "CLINICAL AND PATHOLOGIC SIGNIFICANCE OF INTEGRIN α6β4 EXPRESSION IN 
HUMAN MALIGNANCIES" (2015). Theses and Dissertations--Clinical and Translational Science. 2. 
https://uknowledge.uky.edu/cts_etds/2 
This Doctoral Dissertation is brought to you for free and open access by the Behavioral Science at UKnowledge. It has 
been accepted for inclusion in Theses and Dissertations--Clinical and Translational Science by an authorized 
administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my thesis or dissertation and abstract are my original work. Proper attribution 
has been given to all outside sources. I understand that I am solely responsible for obtaining 
any needed copyright permissions. I have obtained needed written permission statement(s) 
from the owner(s) of each third-party copyrighted matter to be included in my work, allowing 
electronic distribution (if such use is not permitted by the fair use doctrine) which will be 
submitted to UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s thesis including all 
changes required by the advisory committee. The undersigned agree to abide by the statements 
above. 
Rachel L. Stewart, Student 
Dr. Kathleen L. O’Connor, Major Professor 
Dr. Anita Fernander, Director of Graduate Studies 
CLINICAL AND PATHOLOGIC SIGNIFICANCE OF
INTEGRIN 6 4 EXPRESSION IN HUMAN 
MALIGNANCIES
DISSERTATION
A dissertation submitted in partial fulfillment of 
the requirements for the degree of Doctor of Philosophy in 
the College of Medicine at the 
University of Kentucky 
By 
Rachel Lauren Stewart, D.O.
Lexington, Kentucky 
Director: Dr. Kathleen L. O’Connor, Professor of Molecular 
and Cellular Biochemistry 
2015
Copyright © Rachel Lauren Stewart 2015 
ABSTRACT OF DISSERTATION 
CLINICAL AND PATHOLOGIC SIGNIFICANCE OF INTEGRIN 6 4 EXPRESSION
IN HUMAN MALIGNANCIES 
Integrins are cellular adhesion  molecules that bind  cells to the extracellular
matrix. The integrin 6 4, a receptor for laminins, is predominantly expressed on
epithelial cells where it is present at the basal surface adjacent to the basement
membrane. This integrin plays a critical role in maintaining normal cellular functions, yet
has also been implicated in promoting invasion and metastasis in human malignancies.
While overexpression of the integrin 6 4 has been detected in select human cancers,
the clinical significance of integrin 6 4 expression in a number of malignancies has not
been determined. The purpose of this study was to examine integrin 6 4 expression as
it relates to clinical variables and patient outcomes in tumors of the lung, breast, and
central nervous system. In order to study integrin 6 4 protein expression in patient-
derived tumors, tissue microarrays were constructed and sections were stained using
immunohistochemistry for the integrin 4 subunit. Integrin 4 mRNA levels in patient-
derived tumors were also examined using publicly available gene expression datasets.
Integrin 4 expression was found to be elevated in lung squamous cell carcinoma, and
its overexpression was associated with venous invasion and decreased overall survival
among patients with non-small cell lung cancer. In gliomas, integrin 4 was highly
expressed in glioblastomas when compared to lower grade gliomas and non-neoplastic
brain tissue. Integrin 4 expression was shown to be an adverse prognostic marker in
gliomas, and furthermore, integrin 4 expression was reduced in gliomas with mutations
in IDH1. In breast cancer, integrin 6 4 expression was found to be elevated in triple
negative tumors, and in one cohort, elevated integrin 4 expression was associated with
HER2 overexpression. In summary, I have shown that integrin 4 expression is elevated
in a number of aggressive human malignancies, and that its expression associates with
poor prognosis in these tumors. 
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CHAPTER 1: INTRODUCTION*
Integrins are cellular adhesion molecules that serve as receptors for extracellular 
matrix (ECM) components and select cell adhesion molecules. Named for their ability to 
integrate signals from the extracellular environment to the inside of the cell, integrins are 
responsible for securing cells to the surrounding adhesion molecules while amplifying 
and potentiating signals from growth factor receptors and other extracellular stimuli.1
These transmembrane proteins permit cells to sense and respond to their environment 
and thus play critical roles in maintaining normal cellular functions, yet have also been 
implicated in promoting invasion and metastasis in human malignancies.2  
Integrins are heterodimeric receptors that consist of paired α and β subunits. In 
the human genome, there are 18 α and 8 β subunits that combine in a limited 
combination to provide 24 integrin receptors, each with its own specificity for select ECM 
or cellular adhesion proteins (for review, see 1,3). Integrins containing the α6 subunit are 
laminin receptors in which the α6 subunit can pair with either the β1 or β4 subunit. In 
contrast, the integrin β4 subunit can only pair with the α6 subunit,1,2,4 thus making β4 
subunit expression predictive of integrin α6β4 expression.
Integrin α6β4 is predominantly expressed on epithelial cells where it is present at 
the basal surface adjacent to the basement membrane where it nucleates the formation 
of hemidesmosomes. These stable adhesions are critical for the integrity of epithelial 
monolayers. In contrast to this function, integrin α6β4 signaling in various cancers 
promotes an invasive and metastatic phenotype. This functional change is mediated by 
phosphorylation of the cytoplasmic tail of the integrin β4 subunit that releases integrin 
α6β4 from hemidesmosomes and allows the integrin to promote invasive signaling 
through cooperation with growth factor receptors and alteration of the transcriptome, 
which in turn facilitates tumor progression.2,4-9  
*ADAPTED FROM: Stewart RL, O'Connor KL. Clinical significance of the integrin α6β4 in 
human malignancies. Laboratory Investigation. 2015.
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Structure and normal function of integrin α6β4
The α6β4 integrin is a specialized integrin that is expressed in various normal 
epithelia, Schwann cells and endothelial cells. The integrin β4 subunit is distinct from 
other integrin subunits in that it has a particularly long cytoplasmic signaling domain. 
Whereas the cytoplasmic domains of other integrin subunits are less than 50 amino 
acids in length, the integrin β4 subunit is over 1000 amino acids in length.10,11 As 
depicted in Figure 1.1, the cytoplasmic domain of the integrin β4 subunit is characterized 
by two pairs of fibronectin type III domains, a Calxβ domain and a connecting segment.12
The fibronectin repeats and the connecting segment are necessary for hemidesmosome 
assembly.13-15
At the basal surface of normal cells adjacent to the basement membrane, integrin 
α6β4 binds to laminins in the ECM and facilitates stable adhesion through the formation 
of hemidesmosomes. Hemidesmosomes are large adhesion complexes that anchor the 
basal layer of epithelial cells to the basement membrane.13-15 In these junctions, the 
α6β4 integrin nucleates the connection between cytokeratin intermediate filaments in the 
cell and laminins in the basement membrane through its interactions with plectin, 
collagen XVII/BP180 and BP230, as depicted in Figure 1.1B.16,17 The importance of 
these junctions is highlighted by the fact that mutations in the integrin β4 gene (ITGB4)
can cause lethal forms of epidermolysis bullosa with pyloric atresia, a disorder 
characterized by blistering and ulceration of the skin and mucosal tissues.18 While it has 
been suggested that other integrins may be able to compensate for a loss of integrin 
α6β4, studies in mouse models have demonstrated that this is not the case.19 Integrin β4 
knockout mice (-/-) are born with severe epidermal blistering, exhibit widespread 
separation of the epithelial-mesenchymal junction, and die shortly after birth. These 
observations emphasize the importance of the integrin β4 subunit in maintaining the 
integrity of the epithelial-ECM junction.19
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Figure 1.1: Integrin α6β4 structure and hemidesmosome assembly. A) The integrin 
β4 subunit only pairs with the α6 subunit. The long cytoplasmic domain of β4 is 
structurally distinct from other known receptors but contains several distinct domains 
including a Calx-β domain, four fibronectin type III repeats, a connecting segment and C-
terminal tail. B) Integrin α6β4 nucleates hemidesmosomes by binding to multiple 
hemidesmosomal associated proteins including Plectin (HD1), BP180 (also known as 
BPAG2 or collagen XVII) and BP230 (also known as BPAG1). 
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Hemidesmosomes are dynamic structures. During wound healing, 
hemidesmosomes must be dismantled to allow the leading edge cells to migrate into the 
wound.14,20 This functional change is mediated by phosphorylation of the cytoplasmic tail 
of the integrin β4 subunit that releases integrin α6β4 from hemidesmosomes. This 
process occurs through stimulation by growth factor receptors such as the epidermal 
growth factor receptor (EGFR), and by direct phosphorylation of the integrin β4 
cytoplasmic tail by protein kinase C.7,8,21 Upon release from hemidesmosomes, integrin 
α6β4 relocalizes from the keratin cytoskeleton to the actin cytoskeleton.22 When bound 
to F-actin, the integrin α6β4 signaling domain promotes the formation of motility 
structures, such as filopodia and lamellae, by cooperating with growth factor receptors 
and stimulating key signaling pathways6,7,22-24 that in turn facilitate migration and wound 
closure.  
Integrin α6β4 and hemidesmosomes are also suggested to play a role in the 
contextual orientation of cells. When cells are not adhered to the proper extracellular 
matrices, they will undergo a specialized form of apoptosis known as anoikis. Notably, 
when caspases are activated, the β4 cytoplasmic tail is cleaved leading to apoptosis.25,26  
Integrin α6β4 signaling in malignant cells
Release of integrin α6β4 from hemidesmosomes can lead to altered signals that 
promote tumor cell growth, invasion and metastasis.2,4-9 Under conditions where 
hemidesmosomes are disassembled, integrin α6β4 binding directly to laminin has been 
shown to activate both phosphoinositide 3-OH kinase (PI3K) and RhoA small 
GTPases.6,24 Alternatively, the integrin can cooperate with multiple different growth factor 
receptors including those in the EGF receptor family (ErbB-1,2,3), c-Met, Ron, LPA1 and 
LPA223,27-30 to enhance signaling through PI3K, AKT, MAPK and the Rho small 
GTPases,6,23,24,31,32 as depicted in Figure 1.2. In cells with mutant p53, the α6β4 integrin 
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promotes cell survival through activation of AKT/PKB,31 and stimulates cell cycle 
progression and proliferation by interacting with Shc to activate the Ras-MAPK 
pathway.32 As shown in breast and pancreatic cancers, this integrin can promote tumor 
progression through transcriptional regulation and has been shown to increase the 
expression of invasive and metastatic proteins such as the epithelial to mesenchymal 
transition (EMT)-associated protein S100A4 (also known as metastasin/FSP).33-35 In the 
next several sections, I discuss our current understanding of how integrin α6β4 signaling 
promotes a malignant phenotype with an emphasis on its impact on invasion, cell 
survival and angiogenesis. 
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Figure 1.2: Cancer progression-associated signaling pathways activated by 
integrin α6β4. Integrin α6β4 can activate multiple signal transduction cascades either 
directly by binding its ligand laminin or by amplifying signals from multiple growth factors. 
Enhanced signaling through these pathways contributes to tumor progression in terms of 
enhanced proliferation, cell survival, invasion and metastasis. Notably, integrin α6β4 can 
act as a tumor suppressor by promoting apoptosis in the presence of a wild-type p53. 
For this reason, integrin α6β4 is often overexpressed primarily in tumor types where p53 
mutations are prominent such as pancreatic and basal-like breast cancers. 
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Invasive signaling functions
The finding that integrin α6β4 mediates stable adhesive complexes that anchor 
cells to the basement membrane would seem to argue against the participation of 
integrin α6β4 in cell migration. Despite this apparent contradiction, numerous studies 
have confirmed that integrin α6β4 is responsible for promoting migratory and invasive 
behavior in carcinoma cells. A potential explanation for this phenomenon comes from its 
normal role in wound healing,14,20,36 as described above.
Early studies in colon and breast carcinoma lines demonstrated that expression 
of integrin α6β4 contributes to tumor cell invasiveness.6,9,37 These studies lead to the 
pivotal discovery that integrin α6β4 can promote invasive properties in carcinoma cells 
by activating the PI3K pathway,6 a signaling pathway that is now well known for its role 
in promoting carcinoma progression.38 Notably, this was the first time that PI3K had 
been implicated in carcinoma invasion. This finding was subsequently confirmed in a 
number of additional reports,39-41 although the exact mechanism by which integrin α6β4 
activates PI3K initially remained elusive. The cytoplasmic domain of the integrin β4 
subunit does not contain a consensus-binding motif for the regulatory subunit of PI3K, 
making direct activation of this pathway by integrin β4 subunit unlikely.4,6,42 One 
mechanism for integrin β4-mediated activation of PI3K was found to involve insulin 
receptor substrate-1 and -2 (IRS-1 and IRS-2), which act as signaling intermediates that 
facilitate integrin α6β4-mediated PI3K activation.42 Ligation of integrin α6β4 promotes 
phosphorylation of IRS-1 and IRS-2, leading to subsequent activation of PI3K.42 An 
additional mechanism has been described wherein integrin α6β4 cooperates with ErbB-2
to promote PI3K-dependent invasion.39 Finally, integrin α6β4 has been shown to localize 
to lipid rafts in the plasma membrane, which may allow it to activate PI3K by facilitating 
close interactions with other receptor tyrosine kinases.4,40
The involvement of integrin α6β4 in cell polarization and the formation of F-actin 
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rich motility structures such as filopodia and lamellae lead to investigations into the Rho 
family of small GTPases. The Rho family of small GTPases largely control the 
reorganization of the actin cytoskeleton needed for cell motility.43 Initial studies by Shaw 
and colleagues on the activation and function of PI3K in invasion found that the small 
GTPase Rac1 was required for invasion downstream of PI3K,6 a finding confirmed by 
others.44 Notably, integrin α6β4 can cooperate with growth factor receptors45 and other 
integrins23 to activate Rac1. Further studies examining the impact of integrin α6β4 on 
migration and invasion found that integrin α6β4 increased the activity of cAMP-specific 
phosphodiesterase, thereby resulting in decreased cAMP concentrations and 
subsequent RhoA activation.9,24 The activation of RhoA downstream of integrin α6β4 
subsequently leads to the formation of RhoA-dependent membrane ruffling and lamellae 
formation, as well as the generation of contraction forces that enable cell migration.24,46
Our group found that the metastasis associated protein S100A4, which is regulated by 
integrin α6β435 interacts with Rho effector Rhotekin to promote cell membrane ruffling.47
Notably, the traditional function for RhoA is the generation of stress fibers rather than 
membrane ruffling, suggesting that integrin α6β4 can change the function of RhoA to 
facilitate tumor invasion. 
Integrin α6β4 amplifies signaling through multiple receptor tyrosine kinases and 
G-protein coupled receptors in order to promote tumor cell proliferation and invasion. 
Notably, cooperative signaling has been identified between integrin α6β4 and multiple 
members of the EGFR family. EGFR and integrin α6β4 have also been shown to co-
localize at the leading edge of carcinoma cells subjected to EGF stimulation, and 
notably, their interaction is inhibited by curcumin, a compound present in turmeric.48
Integrin α6β4 has also been shown to associate with ErbB-2 in multiple breast 
carcinoma cell lines,30,49 though reports are conflicting as to whether integrin α6β4 
expression correlates with ErbB-2 protein overexpression in patient-derived carcinoma 
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tissues.50-53 Using a mouse model of ErbB-2 mediated tumorigenesis, loss of integrin β4 
signaling was shown to reduce breast tumor invasive growth and metastasis, and 
deletion of the integrin β4 signaling domain was shown to enhance the efficacy of 
ErbB2-targeted therapy.27 This study also demonstrated that the integrin β4 subunit 
forms a complex with ErbB-2 and amplifies ErbB-2 signaling. In addition, integrin α6β4 
has been shown to regulate the expression of ErbB-2 by influencing its translation.54
These findings are particularly notable as ErbB-2 amplification promotes invasion in 
human malignancies such as breast carcinoma, and is associated with aggressive 
behavior.55,56
While an interaction with ErbB-2 may be necessary in order for integrin α6β4 to 
activate PI3K mediated invasion in select cell types, ErbB-2 lacks a consensus-binding 
site for the regulatory subunit of PI3K. Furthermore, ErbB-2 must dimerize with an EGFR 
family member in order to function.30,57 A potential solution to this issue was suggested 
by the finding that integrin α6β4-mediated PI3K activation is dependent on ErbB-2/ErbB-
3 heterodimerization.30 The ErbB-2/ErbB-3 heterodimer is a strong activator of PI3K,30,58
and the ErbB-3 cytoplasmic domain contains binding sites for the regulatory subunit of 
PI3K.59 Integrin α6β4 can regulate the expression of ErbB-3, leading to an increase in 
ErbB-2/ErbB-3 heterodimerization and subsequent PI3K activation,30 and notably, a 
positive association has been identified between integrin α6β4 and ErbB-3 expression in 
patient-derived tumors.51
Integrin α6β4 can also cooperate with c-Met, a receptor tyrosine kinase that is 
activated by the hepatocyte growth factor (HGF).28,29 In one study, integrin α6β4 was 
shown to form a direct complex with c-Met that promotes HGF dependent invasion.28
Additional studies have shown that while an interaction with integrin α6β4 may contribute 
to c-Met dependent invasion, integrin α6β4 and c-Met are also able to promote invasion 
independently.29 Evidence for a physical association between integrin α6β4 and c-Met is 
10 
controversial;4,29 however, this does not preclude the probability that integrin α6β4 can 
cooperate with c-Met without physical association.  
Ron (“recepteur d'origine nantais”), a tyrosine kinase receptor closely related to 
c-Met, has been shown to form a complex with integrin α6β4 that induces 
hemidesmosome disassembly and the relocation of integrin α6β4 to motility 
structures.36,60 Further studies have shown that Ron activation is important in pancreatic 
carcinoma progression,61,62 and have confirmed that Ron interacts with the integrin β4 
subunit in this setting to disrupt the association between integrin β4 and plectin.60
Cell survival and apoptosis 
Integrin a6β4 promotes either cell survival or apoptosis, depending on the cellular 
context. In normal epithelia, integrins are critical to maintaining cellular growth and 
survival as long as they maintain proper contact with the ECM.63 If anchorage to the 
ECM is lost, the subsequent loss of integrin signaling can inhibit cell growth and promote 
a specialized form of apoptosis referred to as anoikis.63 While tumor suppressive 
functions of the integrin β4 subunit have been identified in bladder,64 colon,65 and breast 
carcinoma66 cell lines, a number of additional studies have indicated that the β4 integrin 
promotes cell survival.19,41,66-68 This dichotomy appears to hinge on the expression and 
mutation status of the p53 tumor suppressor.  
Early experiments demonstrated that expression of the integrin β4 subunit in the 
colon cancer cell line RKO led to increased apoptosis, thus lending support to the notion 
that integrin α6β4 functions as a tumor suppressor.65 Conversely, expression of the β4 
subunit was unable to induce apoptosis in the cell line MDA-MB-435.69 The Mercurio 
group investigated the mechanism underlying this apparent contradiction and observed 
that the RKO and MDA-MB-435 cell lines differed in their p53 mutation status. While 
RKO cells harbor a wild-type p53, the MDA-MB-435 cell line expresses mutant p53.69
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This group demonstrated that integrin α6β4 can trigger apoptosis through p53 activation 
in cells harboring wild-type p53;69 however, in carcinoma cells deficient in p53, integrin 
α6β4 promotes cell survival by activating AKT/PKB31,69 and through translational 
regulation of VEGF expression.68 These findings suggest that tumors expressing high 
levels of integrin α6β4 in conjunction with loss of p53 function are resistant to apoptosis 
and will therefore display a more aggressive clinical course. Interestingly, an association 
between p53 mutations and integrin α6β4 overexpression is present in a number of 
aggressive human malignancies, including basal-like breast cancer, head and neck 
squamous cell carcinoma, and pancreatic ductal adenocarcinoma.50,70-76
Angiogenesis 
In addition to promoting invasive properties in carcinoma cells, the integrin α6β4 
can stimulate invasion and migration of endothelial cells, processes that are necessary 
for pathologic angiogenesis5 (for review, see 77,78). Studies using knockout mice carrying 
a deletion in the signaling domain of the integrin β4 subunit displayed reduced 
angiogenesis in a retinal neovascularization model, and developed smaller and less 
vascularized tumors after subcutaneous implantation.5 The same study demonstrated 
that the integrin β4 subunit could promote both bFGF- and VEGF-induced angiogenesis 
by enhancing signaling through ERK and NF-κB. 
The role of α6β4 in transcriptional regulation
Integrin α6β4 regulates the expression of molecules important for carcinoma 
invasion and metastasis. The best studied of these include NFAT1, NFAT5, S100A4, 
ErbB-2, ErbB-3 and autotaxin. The NFATs, or Nuclear Factors of Activated T-cells, are 
transcriptionally regulated by the α6β4 integrin and drive carcinoma invasion.33 As 
shown in breast cancer, integrin α6β4-mediated upregulation of NFAT1 leads to 
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increased expression of autotaxin (ENPP2), an enzyme that acts as a motility factor by 
promoting LPA production.34,79 Integrin α6β4 can also regulate the expression of ErbB-2
and ErbB-330,54 as mentioned above. 
Interestingly, expression of the α6β4 integrin in MDA-MB-435 cells leads to 
altered expression of over 500 genes.35 One of the most regulated and clinically relevant 
of these genes is S100A4, a calcium binding protein also known as metastasin-1.80
S100A4 promotes tumor metastases80 and is regulated by integrin α6β4 through NFAT5 
activation in conjunction with DNA demethylation of the S100A4 promoter.35 S100A4 
interacts with Rhotekin to promote the formation of an S100A4/Rhotekin/RhoA complex, 
thus allowing RhoA to promote invasion through membrane ruffling.47 Integrin α6β4 has 
also been shown to negatively regulate the expression of miR-92ab and miR-99ab/100 
miRNA families that impact target genes implicated in promoting cell motility.81
Integrin α6β4 expression in human malignancies
Integrin α6β4 was originally identified as a tumor progression antigen by two 
separate groups, one who termed it tumor-specific antigen-180 (TSP-180)82 and the 
other who referred to it as the A9 complex.83 Subsequently, the TSP-180 and A9 
complexes were shown to be identical to integrin α6β4.84,85 During the invasive process, 
integrin α6β4 is released from hemidesmosomes where it can then participate in many 
of the most aggressive properties of advanced carcinomas. Immunohistochemical 
staining in patient-derived tissues confirms that in many cancers, expression and 
localization of integrin α6β4 are altered (as demonstrated in Fig. 3).   
Studies examining integrin β4 expression in patient-derived tissue, in some 
cancer types, have obtained conflicting results. It is unclear whether these contradictory 
findings relate to sample size, cancer subtype examined or the method of detection. 
Some investigators have reported inconsistent immunohistochemical staining for integrin 
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β4 in formalin-fixed, paraffin embedded tissue sections.53 Our group found that 
immunohistochemistry for the integrin β4 subunit is particularly sensitive to the antigen 
retrieval process.72 In addition, different studies have used a variety of clonal antibodies 
to detect integrin β4 expression, which may partially explain the variability in staining 
patterns that has been reported. Below, I discuss the clinical associations of integrin 
α6β4 in various human malignancies, noting where there is disagreement in the 
literature.  
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Figure 1.3: Altered localization of integrin α6β4 expression in invasive breast 
carcinoma. In a dilated duct with benign columnar cell change (left), integrin α6β4 is 
expressed in myoepithelial cells surrounding the duct, but is absent in luminal cells. 
Adjacent nests of invading carcinoma cells (right) display elevated expression of the 
integrin β4. Immunohistochemical staining was performed using the 439-9B antibody as 
described in Chapter 2. Brown staining represents positive expression of the integrin β4. 
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Breast cancer 
In breast cancer, integrin β4 overexpression is associated with aggressive 
behavior and poor prognosis. Given the challenges described with 
immunohistochemistry, gene expression profiling provides an excellent alternative that 
allows for quantitative assessment of integrin β4 expression. One study used gene 
expression profiling and immunohistochemistry of tissue microarray (TMA) sections to 
demonstrate that integrin β4 is overexpressed in basal-like breast cancer.50 This finding 
is particularly notable as basal-like breast cancer is an aggressive subtype that is 
associated with a notoriously poor prognosis.71 This group further developed a 65-gene 
signature that included the top genes whose expression was found to correlate with that 
of integrin β4. This integrin “β4 signature” was shown to be a prognostic indicator that 
could predict both decreased survival and decreased time to recurrence in four breast 
cancer cohorts.50 In other studies, integrin β4 mRNA expression was found to positively 
correlate with nuclear grade and tumor size,53 and elevated integrin α6β4 protein 
expression has been found to associate with decreased survival.86 Co-expression of 
integrin α6β4 and Net1, a RhoA guanine nucleotide exchange factor, has also been 
associated with decreased distant metastasis-free survival.52
In contrast to the findings described above, a number of early reports indicated 
that integrin β4 expression is absent or rare in breast cancers. This observation may be 
due to difficulties with immunohistochemistry on frozen specimens, or may be related to 
the fact that these studies were performed before the modern sub-classification of breast 
cancers was developed. As integrin β4 overexpression is more frequent in triple negative 
breast cancers (TNBCs), and these tumors represent a minority of breast cancers, these 
studies may not have included an adequate number of TNBCs to detect integrin β4 
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overexpression. Two of these early investigations report that integrin β4 expression was 
absent in all invasive breast carcinomas examined,82,87 while another found strong 
integrin β4 staining in only a small subset of breast tumors.88 Others have reported that 
integrin β4 is redistributed over the cell surface in select breast carcinomas.89  Integrin 
β4 expression in ductal carcinoma in situ (DCIS) is also reportedly rare, with expression 
identified in only 20% of cases in one study.90 According to another report, integrin β4 
expression was absent in the neoplastic cells of DCIS and detected only in residual 
myoepithelium.87 Given more recent evidence using gene expression profiling, it is 
reasonable to conclude that at least a certain subset of breast tumors overexpress 
integrin β4, including basal-like breast cancers.  
Bladder cancer
Studies investigating integrin β4 expression in bladder cancer demonstrate that it 
is overexpressed in a proportion of transitional cell carcinomas, and suggest its use as a 
prognostic marker. An early study reported that in normal urothelium integrin α6β4 is 
expressed in the basal layer of urothelial cells where this expression is highly polarized 
and localized to the lamina propria junction. The authors then examined integrin α6β4 
expression in ten low stage bladder cancers, where they found increased, non-polarized 
expression in 80% of tumors.91 A subsequent study by the same group examined 
integrin α6β4 expression in bladder tumors from 57 patients; each case was categorized 
as having negative, weak, or strong expression of integrin α6β4, where weak was 
defined as expression that most closely resembled that of normal urothelium.92 They 
found that patients with weak integrin α6β4 expression had improved survival compared 
to patients with either strong or negative expression.92 Another study examined integrin 
β4 expression in a cohort of patients with non-muscle invasive bladder cancer and found 
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that integrin β4 expression levels were an independent predictor of intravesical 
recurrence after transurethral resection.93
Cervical cancer 
Integrin β4 expression in cervical lesions has been examined primarily in cervical 
intraepithelial neoplasia (CIN) and squamous cell carcinoma. Multiple reports have 
confirmed that the integrin β4 is strongly expressed in invasive squamous cell 
carcinomas of the cervix.94-96 Interestingly, integrin β4 expression positively correlates 
with the degree of squamous atypia in CIN.94,95 In a study of cervical biopsies from 35 
patients, integrin β4 expression was present only in cells of the basal and parabasal
layers of normal ectocervical mucosa, and this pattern was maintained in flat 
condylomas, hyperplastic epithelium, and in CIN I lesions.94 Interestingly, in CIN II-III, 
integrin β4 expression was present throughout the entire thickness of the epithelium, 
with strong staining observed toward the superficial surface. Furthermore, expression of 
integrin β4 was identified in 90% of cervical carcinomas studied, where expression was 
diffusely present in the invasive nests.94
A larger study investigated integrin β4 expression in 40 cervical biopsies. The 
authors describe that in normal ectocervical mucosa, integrin β4 expression was 
localized to the basal aspect of cells in the basal layer of epithelium.95 They found that in 
CIN, expression of the integrin β4 followed the distribution of atypia: for example, in CIN 
II, β4 was expressed throughout the lower 2/3 of the epithelial thickness, while in CIN III, 
β4 was expressed throughout the full epithelial thickness. These findings suggest that 
the integrin β4 may play an early role in promoting the survival and growth of pre-
invasive neoplasms. 
A third study examined expression of the integrin β4 in 20 cases of invasive 
cervical carcinoma and 23 cases of CIN III.96 The invasive cervical carcinomas included 
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examples of well, moderately, and poorly differentiated squamous cell carcinoma, as 
well as three endocervical adenocarcinomas. Diffuse expression of the integrin β4 was 
identified in all 20 cases of invasive carcinoma. In addition, integrin β4 expression was 
identified in all epithelial layers in 65% of CIN III lesions.96  
Head and neck cancer 
In squamous cell carcinomas of the head and neck, integrin β4 is commonly 
overexpressed. An early study of 82 patients with SCC of the head and neck found that 
strong expression of the UM-A9 antigen (later identified as the α6β4 integrin) was 
associated with early relapse and decreased patient survival.97 In another study, integrin 
β4 expression was found to be upregulated in SCCs when compared to normal 
squamous mucosa, although an association was found between loss of integrin β4 
expression and the presence of nodal metastases.98  
Multiple studies using gene expression profiling have confirmed that integrin β4 
gene expression levels are prognostically significant in SCCs of the head and neck. One 
of these reports demonstrated that integrin β4 gene expression was associated with 
decreased survival in a cohort of 66 patients.99 In a larger study, increased integrin β4 
gene expression was associated with the presence of lymph node metastases, distant 
metastases and patient death on univariate analysis, and was an independent predictor 
of distant metastases on multivariate analysis.100
Lung cancer 
Integrin β4 is overexpressed in non-small cell lung cancers, and expression is 
particularly high in pulmonary squamous cell carcinomas. An early study investigated 
expression of the integrin α6β4 in a series of patient-derived lung cancers and found 
moderate to strong expression in all of the squamous cell carcinomas (N = 36) and 
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adenocarcinomas (N = 23) tested, though expression was notably absent in all (N =10) 
of the small cell carcinomas examined.101 Integrin β4 expression was identified in a 
number of non-small cell carcinoma cell lines (A431, A549, DG3), but was absent in the 
single small cell carcinoma cell line tested (AE2).101
In a different study that included uninvolved normal lung tissue, normal alveolar 
epithelial cells were found to be negative for integrin β4 expression, and instead 
exhibited expression of the α1β1 and α3β1 laminin receptors. They further found that 
bronchial and bronchiolar epithelium exhibited weak and inconsistent integrin β4 
expression that was localized to the basement membrane interface. In squamous cell 
carcinomas of the lung, integrin β4 expression was intense and localized to the tumor-
stroma interface.102 In this same study, integrin β4 expression was identified in large cell 
carcinomas of the lung, but was found to be absent in neuroendocrine carcinomas. 
Patriarca et al.103 also found that in normal bronchial epithelium, integrin β4 expression 
was localized to the basal surface of cells in a linear pattern. They found strong and 
extensive staining for the integrin β4 in 85% of squamous cell carcinomas (N = 20), but 
found positive staining in only 25% pulmonary adenocarcinomas studied (N = 20).  In a 
complementary study using molecular profiling, integrin β4 was upregulated in lung 
squamous cell carcinomas when compared to adenocarcinomas, and this was confirmed 
using both immunohistochemistry and in-situ hybridization.104 Additional studies will be 
needed to determine the clinical and prognostic significance of integrin β4 expression in 
non-small cell lung  cancer.  
Pancreatic cancer
Integrin β4 is overexpressed in pancreatic carcinomas, and is also a marker of 
poor prognosis. Using gene expression profiling, Logsdon et al. first determined that 
integrin β4 is upregulated in pancreatic adenocarcinoma when compared to normal 
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pancreatic tissue and chronic pancreatitis tissue samples,105 a finding that was 
confirmed by others.106 In order to validate these findings, the Logsdon group performed 
immunohistochemistry for the integrin β4 subunit and a number of other candidate genes 
in 28 pancreatic adenocarcinomas, where they found that all cases had strong integrin 
β4 expression.105 In another report, Gleason et al. found moderate to strong integrin β4 
staining in 92% (N = 48) of pancreatic adenocarcinomas that were evaluated using 
immunohistochemistry; they also found that in normal pancreas, integrin β4 staining was 
weak and expressed only along the basement membranes of large ducts.107
Integrin β4 expression has also been studied in pancreatic intraepithelial 
neoplasia, a non-invasive precursor lesion to pancreatic adenocarcinoma.108 In a 
comprehensive study of pancreatic lesions, Cruz-Monserrate et al.72 determined that 
integrin β4 overexpression is present in the early stages of pancreatic adenocarcinoma 
development. As reported previously, they found that in normal pancreas, integrin β4 
expression is localized to the interface between ductal epithelial cells and the basement 
membrane.72 Upregulation of integrin β4 expression was observed in 92% (N = 113) of 
pancreatic adenocarcinomas studied, and distinguished pancreatic cancer from 
pancreatitis.  Furthermore, overexpression and altered localization of the integrin β4 was 
identified in all pancreatic intraepithelial neoplasia lesions ranging from Grade 1A to 
Grade 3.72
Recently, elevated integrin β4 expression was shown to associate with reduced 
overall survival among pancreatic adenocarcinoma patients (N = 134), where it was 
found to have independent prognostic significance on multivariate analysis. Interestingly, 
elevated integrin β4 expression was also found to correlate with a number of EMT 
hallmarks, including solitary cell infiltration, reduced expression of E-cadherin, and 
increased expression of vimentin.109 Pancreatic adenocarcinoma has one of the poorest 
prognoses of all epithelial malignancies; the fact that integrin β4 is highly expressed in 
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these tumors provides further evidence for its role in aggressive neoplasms. 
Thyroid cancer 
Thyroid carcinomas are unique in that they are one of the few malignancies to 
exhibit neoexpression of integrin α6β4 during cancer progression. While expression of 
integrin α6β4 is absent in normal and adenomatous follicular cells, strong expression 
has been observed in both follicular and papillary thyroid carcinomas.110 Similar findings 
have been reported using flow cytofluorometry, where expression of integrins such as 
α1β1 and α6β1 was found in normal thyroid and tumor specimens, integrin α6β4 
expression was found only in thyroid carcinomas and carcinoma cell lines.111 Others 
have confirmed neoexpression of integrin α6β4 in thyroid carcinoma tissue112,113 and
have also found that it is expressed in anaplastic thyroid carcinoma, an aggressive and 
poorly differentiated malignancy.112
Colon cancer 
One of the earliest studies to investigate α6β4 expression in human malignancies 
found that the α6β4 integrin was expressed in colon cancer.82 However, additional 
reports have been controversial. One study investigating integrin β4 expression in 
colorectal carcinomas reported that integrin β4 expression was reduced during 
malignant transformation.114 This group found that while expression of the integrin β4 
subunit was maintained at the basal epithelial cell membrane in normal colonic mucosa 
and in colonic adenomas, expression of the integrin β4 subunit was reduced or absent in 
most colorectal carcinomas, but was maintained in well-differentiated colon cancer.114
Similar findings were reported in another study, where expression of the integrin β4 
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subunit was reduced or absent in most colon carcinomas examined.115
A contrasting study demonstrated that integrin β4 is overexpressed in a majority 
of colon carcinomas and that its expression is elevated in high stage, poorly 
differentiated cancers.116 These findings are supported by subsequent work examining 
integrin β4 expression in colorectal carcinomas using double immunofluorescence and 
RT-QPCR, where integrin β4 protein and transcript levels were increased in colorectal 
carcinoma when compared to normal tissue.117 Data from our laboratory also confirms 
the observation that integrin β4 levels are particularly high in colon cancer cell lines and 
patient-derived tissues (unpublished observation).  
Ovarian cancer 
In benign ovary, integrin β4 is basally located in surface and cyst lining 
epithelium.75 One of the few studies investigating integrin β4 expression in ovarian 
cancer found strong basal expression in all of the epithelial ovarian tumors studied, and 
also found that integrin β4 was expressed in malignant cells within the ascitic fluid in 
three out of nine cases.75 A second report found basally polarized integrin β4 expression 
in normal ovary and in 40% of serous ovarian carcinomas examined. The authors further 
noted that expression of both integrin α6 and β4 subunits were positively correlated with 
laminin expression.74 Interestingly, serous ovarian cancer has a similar genomic profile 
to basal-like breast cancer, with both subtypes displaying frequent loss of TP53, BRCA1,
and RB1, suggesting that integrin β4 may play an important role in both types of 
cancer.70 Further work will be needed to fully characterize integrin β4 expression in 
ovarian neoplasia and to determine how expression associates with prognosis.  
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Prostate cancer 
Early reports indicated that integrin β4 is downregulated in prostatic 
adenocarcinoma, and in one investigation, expression of integrin β4 was absent in all 
prostate cancers examined (N = 20).118 Multiple additional studies have reported that 
integrin β4 expression is lost during the transition from benign epithelium to prostatic 
adenocarcinoma.119-122 A potential explanation for this phenomenon is that androgen 
receptor expression has been reported to cause downregulation of integrin α6β4.123 The 
assertion that integrin β4 is downregulated in prostate cancer was challenged by a report 
demonstrating that integrin β4 mRNA is overexpressed in a subset of prostate 
carcinomas using gene expression datasets and a DNA microarray.124 The authors of 
this study also investigated integrin β4 protein expression using immunohistochemistry 
and found overexpression in 35% of invasive cancers and in a number of metastatic 
lesions.124 More recently, a population of integrin β4 positive circulating tumor cells was 
identified in the peripheral blood of patients with castration resistant prostate cancer.125
Overall, prostate cancer is one cancer in which integrin α6β4 is suggested to be 
downregulated. However, given recent findings, it will be important to determine how 
residual or enhanced integrin α6β4 expression, in the minority of cases that overexpress 
it, associates with clinical parameters. 
Tumors of the central nervous system 
Expression of integrin α6β4 has not been extensively studied in glial tumors; 
however, there is evidence demonstrating that integrin α6β4 is expressed in 
astrocytomas, oligodendrogliomas, glioblastomas, and a number of glioma cell lines. 
Integrin β4 expression has been identified in reactive astrocytes126 as well as in 
subependymal glia, choroid plexus and meningothelial cells.127 One study found that 
integrin β4 expression is higher in astrocytomas and glioblastomas when compared to 
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benign astrocytes.126 A larger study investigated expression of the integrin β4 subunit in 
a series of astrocytomas and oligodendrogliomas where they found that integrin β4 
expression was slightly higher in oligodendrogliomas.128 Further studies will be needed 
to determine how integrin α6β4 relates to glioma stage and prognosis.
Sarcomas 
Integrin β4 overexpression has been described in high-grade osteosarcomas and 
there is evidence it may play a role in promoting a metastatic phenotype by interacting 
with ezrin.129 While integrin β4 is expressed in benign endothelial cells, its expression 
appears to be reduced in angiosarcomas and other vascular tumors.130 Integrin β4 
staining is also reportedly absent in rhabdomyosarcomas, ganglioneuroblastomas, 
primitive peripheral neuroectodermal tumors and Ewing's sarcomas.131
Conclusions
Integrin β4 is commonly overexpressed in high-grade malignancies. Notably, 
there is strong evidence that integrin β4 is overexpressed in tumors of the bladder, 
cervix, lung, pancreas and thyroid. In addition, integrin β4 overexpression has been 
identified as an adverse prognostic marker in tumors of the bladder and pancreas, and in 
squamous cell carcinomas of the head and neck. The reason for these poor prognoses 
stems from the ability of the integrin α6β4 to promote several key hallmarks of cancer, 
including the capacity to sustain proliferative signaling, evade apoptosis, promote tissue 
invasion and metastasis, and stimulate angiogenesis. 
In a number of malignancies, it is still unclear whether expression of integrin β4 is 
elevated or reduced. In tumors of the breast, prostate and colon, a number of studies 
examining integrin β4 expression have obtained conflicting results, with some authors 
reporting that integrin β4 is overexpressed and others reporting a reduction in integrin β4 
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expression. These disparate findings may relate to differences in sample size, antibody 
usage, tissue processing or antigen retrieval process. Because integrin β4 is highly 
expressed at the basal aspect of normal epithelial cells but is redistributed over the cell 
surface during malignant transformation, it may appear in some cases that integrin β4 
expression is reduced. It is likely that altered localization of the α6β4 integrin and its 
concurrent release from hemidesmosomes are as important in carcinoma progression as 
overexpression, thus altered integrin α6β4 localization should be studied carefully in 
these malignancies.  
Study ationale and ypothesis
Our lab previously demonstrated that integrin β4 is highly expressed in 
pancreatic adenocarcinomas, a tumor type with a high frequency of TP53 mutations.72
Notably, mutation or inactivation of TP53 is one mechanism that allows integrin α6β4 to 
promote cell survival and amplify signaling through a number of invasive and 
proliferative pathways. Integrin α6β4 can trigger apoptosis in cells harboring wild-type 
TP53; however, in carcinoma cells with mutant TP53, integrin α6β4 promotes cell 
survival.31,68,69  Interestingly, tumors with a high frequency of TP53 mutations (pancreatic 
adenocarcinoma, basal-like breast cancer, squamous cell carcinomas of the head and 
neck) tend to also display integrin β4 overexpression. In these tumor types, there is 
evidence that integrin β4 expression is clinically significant and associates with a poor 
prognosis. This observation may partially explain why integrin β4 expression is 
prognostically significant in some, but not all tumor types.  
Non-small cell lung cancer (NSCLC) and malignant gliomas are both aggressive 
malignancies that have a high frequency of TP53 mutations. While preliminary studies 
have investigated integrin β4 expression in these tumor types, the pathologic and 
prognostic significance of integrin β4 expression in these cancers remains 
26 
undetermined. I therefore sought to investigate integrin β4 expression in patient-derived 
lung cancers and in malignant gliomas. In order to examine integrin β4 expression in a 
large number of patient-derived tumors, I performed immunohistochemistry of tissue 
microarray sections and analyzed integrin β4 gene expression using gene expression 
databases.  
While a number of studies have investigated integrin β4 expression in breast 
cancer, the significance of integrin β4 overexpression in these tumors remains 
controversial. In addition, integrin β4 expression in ductal carcinoma in situ (DCIS) and 
its clinical significance has not been thoroughly investigated. For these reasons, I sought 
to investigate integrin β4 expression in benign breast, DCIS, and invasive breast cancer. 
Basal-like breast cancer has a high frequency of TP53 mutations and integrin β4 
overexpression has previously been demonstrated in this tumor type.50 In order to study 
integrin β4 expression in these aggressive tumors, a TMA enriched for TNBCs was 
constructed. The hypothesis of this study is that in tumors of the lung, breast, and central 
nervous system, integrin β4 overexpression associates with aggressive behavior and 
reduced patient survival. 
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CHAPTER 2: GENERAL MATERIALS AND METHODS
As described previously, the integrin α6 subunit can pair with either the β1 or β4 
subunit. In contrast, the integrin β4 subunit can only pair with the α6 subunit, therefore 
integrin β4 subunit expression is predictive of integrin α6β4 expression.1,2,4
Immunohistochemistry was performed on formalin fixed paraffin embedded (FFPE) 
tissue sections (4 μm) that had been baked at 60°C for 1 hour. First, sections were 
deparaffinized by washing in xylene three times. The sections then went through three 
washes each in  100% ethanol followed by 95% ethanol, each for 1 minute. Slides were 
then rinsed in a water bath for three minutes. The activity of endogenous peroxidases 
was blocked by placing slides in 3% hydrogen peroxide in phosphate buffered saline 
(PBS, pH 7.4) (P3813) (Sigma-Aldrich, Saint Louis, MO) for 10 minutes. Slides were 
then rinsed with water, and antigen retrieval was performed by placing slides in a 
container filled with 1 X Dako Target Retrieval Solution (S1699) (Dako Corporation, 
Carpinteria, CA, USA), which had been brought to temperature in a steamer at 100°C. 
The slides were kept at 100°C for 20 minutes, and then removed and allowed to cool for 
an additional 20 minutes. After rinsing in water and 1 X PBS with 0.05% Tween-20
(PBST, pH 7.4) (P3563) (Sigma-Aldrich, Saint Louis, MO, USA), blocking was 
performed using an Avidin-Biotin Blocking kit (SP-2001) (Vector Laboratories, 
Burlingame, CA) according to the manufacturer’s instructions. Sections were then 
blocked against non-specific binding by placing them in 1 X PBST and 0.3% casein for 
30 minutes. Next, the sections were incubated with a rat monoclonal primary antibody to 
the integrin β4 subunit (CD 104) (clone 439-9B; BD Pharmingen, San Jose, CA), at a 
concentration of 1:200 in antibody diluent solution (S3022) (Dako Corporation). Slides 
were incubated with the primary antibody for one hour at room temperature, after which 
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antibody (Vector Laboratories, Burlingame, CA) for 30 minutes at room
temperature at a concentration of 1:500 in antibody diluent solution  (S3022) (Dako 
Corporation). After incubation with the secondary antibody, slides were again rinsed 
three times in PBST. Slides were then incubated for 20 minutes with Streptavidin HRP 
(P0397) (Dako Corporation) at a concentration of 1:500 in PBS. Detection was 
accomplished using a 3’3 diaminobenzidine (DAB) developer from a kit manufactured by 
Dako Corporation (K3468). Sections were counterstained with Hematoxylin, rinsed in 
water, and washed three times in 95% ethanol, 100% ethanol, and xylene. The slides 
were then coverslipped using Cytoseal 60 mounting media (Richard-Allan Scientific, 
Kalamazoo, MI). This immunohistochemistry protocol for integrin β4 staining was 
developed by Cruz-Monserrate (14).
Statistical analysis 
Differences between groups were analyzed using chi-square or Fisher’s exact 
test for categorical variables, as appropriate. For continuous variables, two-tailed t-test, 
two-tailed t-test with Welch’s correction, Mann-Whitney test, one-way ANOVA with post 
hoc Tukey’s test, or Kruskal-Wallis test with Dunn's Multiple Comparison Test were 
used, as appropriate. Survival differences were assessed via log-rank tests for 
univariate analyses and Cox proportional hazards for multivariate. Significance was 
reached when P < 0.05. Statistical analyses were performed using GraphPad software 
(La Jolla, CA).
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CHAPTER 3: INTEGRIN α6β4 EXRESSION IN LUNG CANCER
Lung cancer is the leading cause of cancer-related mortality in the United States 
and is a significant problem globally.132 Patients diagnosed with lung cancer have a poor 
prognosis, and over 80% succumb to disease within 5 years of diagnosis.132 Lung
cancer is most often diagnosed between the ages of 40 – 70, with a peak incidence at 
50 – 60 years of age.133 The state of Kentucky is severely affected by lung cancer,
having both the highest incidence and mortality rates for lung cancer in the United 
States. This phenomenon is at least partially explained by the high prevalence of 
tobacco use in this state. 
Evidence demonstrating a link between cigarette smoking and lung cancer is 
overwhelming. Exposure to cigarette smoke is responsible for approximately 80-90% of 
lung cancers in the United States,134 though exposure to a number of additional agents 
can also contribute to the development of lung cancer. These include uranium, asbestos, 
radon, polycyclic aromatic hydrocarbons, arsenic, nickel, vinyl chloride, radiation and air 
pollution.135 In the southeastern United States, occupational exposure related to coal-
mining may also elevate lung cancer risk.136 A small number of lung cancers develop in 
never-smokers, and although rare, these tumors may be attributable to inherited 
mutations such as the T790M mutation in EGFR.137,138
Lung cancer can be categorized into a number of groups based on histologic 
features, immunophenotype and clinical behavior. Broadly, lung cancer can be divided 
into two main categories: small cell lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). SCLC is an epithelial tumor that is notable for its aggressive behavior and 
neuroendocrine phenotype. It is distinct from other lung cancers in both clinical behavior 
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and response to chemotherapy,135 and is often diagnosed at an advanced stage.
Morphologically, SCLC is characterized by small, round to oval cells with scant 
cytoplasm (Fig. 3.1). The nuclei are hyperchromatic with finely granular chromatin, 
leading to the common descriptor “salt and pepper” chromatin. SCLC exhibits 
neuroendocrine differentiation, and typically expresses chromogranin, synaptophysin, 
CD56, and other neuroendocrine markers.135 In accordance with their notoriously 
aggressive behavior, the proliferation rate of these tumors reaches nearly 100% as 
measured using Ki-67 immunohistochemistry.135 The presence of zonal necrosis is 
another characteristic feature of SCLC.
The pathogenesis of SCLC includes aberrations in Notch and Hedgehog 
signaling that mimic processes found in early lung development.139  Genomically, SCLC 
is characterized by a high frequency of TP53 mutations, inactivation of RB, deletion of 
chromosome 3 (p14-p23) and upregulation of BCL-2.139 Unfortunately, study of these 
tumors is limited somewhat by the fact that pathologic material is difficult to obtain. 
Because of the aggressive nature of SCLC, surgical resection is rarely attempted, and 
hence, only small biopsies or fine needle aspiration specimens are available for analysis.
These factors limited the examination of integrin β4 expression in SCLC in this study.
NSCLC is the most common form of lung cancer and accounts for 80% of 
lung cancer diagnoses. NSCLC can be further divided into a variety of histologic 
subtypes, the most common of which include adenocarcinoma (ADC), squamous cell 
carcinoma (SCC) and large cell carcinoma (LCC). There are a few additional histologic 
subtypes that are less frequently encountered; these include adenosquamous 
carcinoma, sarcomatoid carcinoma, giant cell carcinoma, and carcinoid tumors. Although 
exceedingly rare, analogues of salivary gland tumors are occasionally observed in the 
lung and bronchus.
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Figure 3.1: Histologic features of SCLC and NSCLC.  
SCLC demonstrating small, round to oval cells with hyperchromatic nuclei and scant 
cytoplasm (A). NSCLC with eosinophilic cytoplasm, pleomorphic vesicular nuclei and
prominent nucleoli (B). Magnification = 200x, all images.  
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Adenocarcinoma is the most common type of lung cancer in the United States.133
Histologically, adenocarcinoma is characterized by glandular differentiation and the 
presence of intracytoplasmic mucin.135 Poorly differentiated adenocarcinomas may lack 
characteristic morphologic features thus requiring the use of immunohistochemistry to 
arrive at a pathologic diagnosis. Adenocarcinomas are often positive for expression of 
TTF-1, Napsin A, and CK7 by immunohistochemistry.140 Genomic alterations frequently 
observed in lung adenocarcinoma include mutations in KRAS, EGFR, and TP53.135
Fusions involving ALK, ROS1, and EML4 have also been identified.141,142 Although rare, 
HER2 mutations also occur in lung adenocarcinomas and clinical trials targeting these 
mutations are ongoing.143  
Squamous cell carcinomas (SCC) of the lung frequently display intracellular 
bridges, and in well to moderately differentiated tumors, distinctive keratin pearls may be 
noted.135 Poorly differentiated SCCs can often be distinguished from lung 
adenocarcinoma by positive immunohistochemical staining for CK5/6, p63, and p40, and 
by negative staining  for  TTF-1.144 SCCs have a high frequency of TP53 mutations, with 
some sources reporting these mutations in greater than 80% of cases.145 Lung SCC 
carries a poor prognosis and is typically treated with surgical resection, radiation and 
traditional cytotoxic chemotherapy. While a number of targeted therapies have recently 
been developed for the treatment of NSCLC, these agents target genomic alterations 
that occur more frequently in lung adenocarcinoma, such as mutations in EGFR and 
rearrangements of ALK and ROS1.146-149 Squamous cell carcinomas lack targeted 
therapies and display notoriously aggressive behavior. 
In carcinoma cells with mutant TP53, the integrin β4 promotes cell survival by 
activating AKT.31 Interestingly, TP53 mutations and integrin β4 overexpression co-occur 
in many aggressive malignancies, including basal-like breast cancer, serous ovarian 
carcinoma, and pancreatic ductal adenocarcinoma.50,70-76 Given that lung SCC has a 
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high frequency of TP53 mutations, I predicted that integrin β4 expression in this tumor 
type would associate with aggressive behavior and poor prognosis. While preliminary 
investigations into integrin β4 expression in NSCLC have been published previously, an 
association has not been demonstrated between integrin β4 overexpression and clinical 
outcomes.101-104 We therefore sought to investigate integrin β4 expression as it relates to 
histologic subtype, clinicopathologic features and patient survival in lung cancer. Here, I 
report that integrin β4 is highly expressed in lung SCC, and that its overexpression is 
associated with decreased overall survival in NSCLC patients.  
Materials and Methods 
Lung cancer tissue microarray construction 
Institutional Review Board Approval (13-0692-P6H) was obtained prior to 
initiating the project. Surgical resections for NSCLC performed at the University of 
Kentucky from 2006-2010 were identified using natural language searches in CoPath 
(Cerner Corporation, Kansas City, MO). Cases were excluded if the primary tumor was 
not of lung origin, or if adequate pathologic material was not available. A total of 216 
cases were selected, including 83 adenocarcinomas, 102 squamous cell carcinomas, 12 
adenosquamous carcinomas, 12 poorly differentiated carcinomas, 2 large cell 
neuroendocrine carcinomas, 1 giant cell carcinoma, 1 pleomorphic carcinoma, 1
sarcomatoid carcinoma and 2 tumors with mixed histology (mixed adenocarcinoma and 
large cell neuroendocrine). For each case, I reviewed the original hematoxylin and eosin 
(H&E) stained slides and selected representative tumor blocks. Fresh H&E stained 
sections were then cut from each selected block. These fresh sections were again 
reviewed, and tumor areas were selected for inclusion in the arrays.  Pathologic features 
(tumor grade, tumor size, histologic type, pTNM staging, presence of lymphovascular,
venous, and pleural invasion) were abstracted from pathology records using CoPath 
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(Cerner Corporation, Kansas City, MO). Treatment and outcome data were collected by 
the Cancer Research Informatics Shared Resource Facility. Listing of randomly-sorted 
samples for allocation into the recipient TMA blocks was generated by the MCC 
Biostatistics and Bioinformatics Shared Resource Facility. Assembly of TMA blocks (12 
in total) was performed by the MCC Biospecimen and Tissue Procurement Shared 
Resource Facility. Three 2 mm diameter tissue cores were obtained from each tumor 
specimen, which were transferred to recipient paraffin blocks using a TMArrayer 
(Pathology Devices, Westminster, MD). TMA sections used for integrin β4 
immunohistochemistry had interpretable tissue cores in 211/216 cases. Patient 
characteristics for these 211 cases are summarized in Table 3.1.
Immunohistochemistry Scoring and Analysis 
Immunohistochemistry was performed according to the protocol described in 
Chapter 2. Specifically, the primary antibody (439-9B) was used at a concentration of 
1:200 and the secondary antibody was used at 1:500. A semi-quantitative scale was 
used to score integrin β4 expression as follows: negative (0), weak (1), moderate (2), 
strong (3). Results from each of the three tissue cores were averaged to produce a final 
score for each tumor. As integrin β4 was expressed at moderate (2) levels in benign 
bronchial epithelium, we defined integrin β4 overexpression as an average score of ≥ 
2.5. 
Data Mining 
Multiple lung cancer gene expression datasets were analyzed for ITGB4 
expression. The first of these was a NSCLC dataset generated by the Cancer Genome 
Atlas Research Network (TCGA, http://cancergenome.nih.gov/) containing 155 SCC
samples and 32 ADC samples that were analyzed using a custom Agilent microarray. 
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The second was a dataset generated by Hou et al. containing 91 NSCLCs and 65 
adjacent normal lung samples that had been analyzed using a Human Genome U133 
Plus 2.0 Array (Affymetrix, Santa Clara, CA).150 These datasets were accessed and 
downloaded using The Oncomine™ Platform (Life Technologies, Ann Arbor, MI). The 
UCSC Cancer Browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/) was 
used to download a processed lung SCC gene expression dataset (N = 155) in order to 
study genes correlated with ITGB4.145,151 In addition, cBioPortal 
(http://www.cbioportal.org/) was used to generate a network map showing the 50 most 
highly altered genes neighboring ITGB4 in the TCGA lung SCC dataset.152,153
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Table 3.1: Lung tissue microarray patient and tumor characteristics. 
Patient Characteristics
Age at diagnosis, mean 63 (range 39-84)
Gender
Female 88 (42%)
Male 123 (58%)
Smoking Status
Patients with data 159
Smoker 154 (97%)
Never smoker 5 (3%)
Residence
Appalachian 145 (69%)
Non-Appalachian 59 (28%)
Out of state 7 (3%)
Vital Status
Alive 89 (42%)
Deceased 122 (58%)
Tumor characteristics
Histology
Adenocarcinoma 81 (38%)
Squamous cell carcinoma 99 (47%)
Other 31 (15%)
Differentiation
Well 12 (6%)
Moderate 87 (41%)
Poor 112 (53%)
AJCC Stage
I 108 (51%)
II 37 (18%)
III 44 (21%)
IV 13 (6%)
Unknown 9 (4%)
Total  211
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Results
Patient and tumor characteristics 
The mean age at diagnosis for patients in this study was 63.4 (range 39-84), with 
a median of 63 years. Lung cancer was more frequently diagnosed in males (58%) than 
in females (42%). Of patients with data available on tobacco use, 97% had a smoking 
history while only 3% were never smokers. Squamous cell carcinoma was the most 
common histologic type and accounted for 47% of cases, while adenocarcinoma 
accounted for 38% of cases. Most tumors were moderate (41%) or poorly (53%) 
differentiated, with only a small number of well differentiated tumors (6%). The well 
differentiated tumors tended to be bronchoalveolar carcinomas (92%). As patients with 
localized disease are more frequently treated with surgical resection, there was a
predominance of American Joint Committee on Cancer (AJCC) Stage I and II cases, 
with only 6% Stage IV cases.  
Comparison of integrin β4 expression in benign and neoplastic lung 
In an external gene expression dataset, NSCLCs were found to have elevated 
integrin β4 expression when compared to normal lung tissue (Fig. 3.2A; P <0.0001). 
Although normal lung tissue was not specifically selected for inclusion in the tissue 
microarrays, benign bronchial epithelium was identified in a subset of tissue cores. In 
pseudostratified columnar epithelium, integrin β4 was primarily expressed in basal cells 
and along the basement membrane (Fig. 3.2B). Weak staining was also present at the 
apical surface of ciliated columnar cells, while goblet cells and immune cells in the 
bronchial epithelium were negative for integrin β4 expression. In a few cases, benign 
bronchial epithelium was identified adjacent to invasive carcinoma cells. Here, integrin 
β4 expression was higher in the invasive carcinoma (Fig. 3.2C-D). In addition, basal 
polarization of integrin β4 expression was lost in invasive carcinoma.  
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Expression and localization of the integrin β4 in NSCLC
Integrin β4 expression was found to be highly variable in NSCLCs: some cases 
exhibited strong and diffuse staining while others were completely negative for integrin 
β4 expression (Fig. 3.3A-D). In some tumors, staining was predominantly membranous, 
while others exhibited a mixture of cytoplasmic and membranous immunoreactivity (Fig. 
3.4A-B). Integrin β4 staining intensity was elevated at the tumor-stromal interface in 
some tumors, a phenomenon that has been previously described by others (Fig.3.4C).102
Individual infiltrating tumor cells and nests at the invasive front also tended to have 
elevated integrin β4 expression compared to cells at the center of the tumor (Fig. 3.5).  
Integrin β4 expression and association with clinical features
In our TMA cohort, integrin β4 expression was elevated in squamous cell 
carcinomas when compared to adenocarcinomas (Fig. 3.6A; P < 0.0001); this finding 
was confirmed in two external gene expression datasets (Fig. 3.6B-C; P < 0.0001). 
Integrin β4 protein expression was also elevated in a subset of adenosquamous 
carcinomas and poorly differentiated tumors that were evaluated in our TMA (Table 3.2).
Using data abstracted from pathology reports, integrin β4 overexpression was found to 
associate with the presence of venous invasion (Fig. 3.7; P = 0.0037). To date, no data 
have been published that demonstrate an association between integrin β4 expression
and patient outcome in NSCLC. In our TMA cohort, integrin β4 overexpression was 
significantly associated with shorter overall survival (Fig 3.8A; hazard ratio 1.457, 95% 
confidence interval 1.013 to 2.094, P = 0.0422). This relationship was also significant 
when using a higher cutoff point to define integrin β4 overexpression (Fig. 3.8B; hazard 
ratio 1.714, 95% confidence interval 1.171 to 2.510, P = 0.0056). Furthermore, elevated 
integrin β4 gene expression in the Hou dataset was associated with reduced one year 
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survival (Fig. 3.8C; P = 0.0062), and showed a trend towards reduced overall survival 
(Fig. 3.8D; hazard ratio 1.674, 95% confidence interval 0.8977 to 3.120, P = 0.1051). In 
the TCGA dataset, higher levels of integrin β4 gene expression were associated with 
reduced overall survival (Fig. 3.8E-F; hazard ratio 1.714, 95% confidence interval 1.052 
to 2.792, P = 0.0305). cBioportal was used to generate a list of genes most positively 
correlated with ITGB4 in squamous cell lung cancers. ITGB4 expression was highly 
correlated with expression of stem cell markers ITGA6 and CD44 (Figure 3.9A-B; P <
0.0001). Expression of EGFR was also highly correlated with ITGB4 expression (Fig. 
3.9C). In addition, a network map was generated using cBioPortal. This map 
demonstrates highly altered genes neighboring ITGB4 (Fig. 3.10). These genes included 
various laminins, collagens, CD151, the Myc pathway, EGFR, Met, Yes and genes in the 
PI3K-AKT pathway.
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Figure 3.2: Expression of the integrin β4 in benign and neoplastic lung. In the Hou 
dataset, NSCLCs had greater average levels of ITGB4 mRNA than normal lung, P <
0.0001 via two tailed t-test with Welch's correction (A). In benign bronchial epithelium, 
integrin β4 had moderate expression in basal cells and along the basement membrane, 
with weak expression at the apical surface of ciliated columnar cells (B). However, in 
invasive carcinoma, integrin β4 was overexpressed and basal polarization was lost (C,
D).
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Figure 3.3: Integrin β4 staining intensity in non-small cell lung carcinoma. 
Examples of negative (A), weak (B), moderate (C), and strong (D) integrin β4 expression 
in NSCLCs. Left panels show integrin β4 staining, right show H&E. Magnification = 200x, 
all images.    
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Figure 3.4: Localization of integrin β4 staining in NSCLC. Some cases exhibited 
predominantly membranous staining (A), while others had strong membranous and 
cytoplasmic expression of the integrin β4 (B). In some cases, integrin β4 was elevated
predominantly at the tumor-stroma interface (C). Magnification = 200x, all images. 
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Figure 3.5: Integrin β4 expression at the invasive front. Integrin β4 expression is 
elevated in infiltrating cells at the invasive front of a poorly differentiated NSCLC.   
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Table 3.2: Integrin β4 expression in NSCLC by histologic subtype. 
Integrin β4 High Integrin β4 Low 
Total 101/211 (48%) 110/211
Histologic Type:
Squamous cell carcinoma 77/99 (78%) 22/99 (22%)
Adenocarcinoma 11/81 (14%) 70/81 (86%)
Other histologic types:
Poorly differentiated 5/12 (42%) 7/12 (58%)
Adenosquamous 7/12 (58%) 5/12 (42%)
Mixed histology 1/2 (50%) 1/2 (50%)
Large cell neuroendocrine 0/2 (0%) 2/2 (100%)
Pleomorphic carcinoma 0/1 (0%) 1/1 (100%)
Giant cell carcinoma 0/1 (0%) 1/1 (100%)
Sarcomatoid carcinoma 0/1 (0%) 1/1 (100%)
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Figure 3.6: Integrin β4 expression in NSCLC by histologic subtype. SCCs had a 
higher proportion of cases with integrin β4 overexpression than did adenocarcinomas, as 
measured using semi-quantitative IHC, P < 0.0001 via Mann-Whitney test (A). In a 
TCGA NSCLC dataset, average ITGB4 mRNA expression was higher in SCCs than in 
adenocarcinomas, P = 0.0001 via two-tailed t-test (B), and in the Hou dataset, average 
ITGB4 mRNA expression was higher in SCCs when compared to both normal lung 
tissue and adenocarcinomas, P < 0.0001 via one-way ANOVA with post hoc Tukey’s test
(C).  
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Figure 3.7: Integrin β4 is elevated in tumors with venous invasion. Integrin β4 
overexpression is associated with the presence of venous invasion, P = 0.0037 via 
Mann-Whitney test (A). An example of a tumor from the TMA with venous invasion, 
stained for integrin β4 and elastic trichrome (B). In the elastic trichrome, black staining 
highlights elastic fibers of the vein wall, and tumor fills the vessel.   
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Figure 3.8: Integrin β4 and survival in NSCLC. In our TMA cohort, elevated 
expression of integrin β4 was associated with shorter median overall survival, P =
0.0422 (A) and P = 0.0056 (B). In the Hou cohort, average ITGB4 mRNA levels were 
higher in patients that were deceased at one year (C), and there was a trend towards 
reduced overall survival for patients with elevated ITGB4 mRNA expression (D). In the 
TCGA cohort, elevated ITGB4 mRNA expression was associated with reduced overall 
survival depending on the cutoff point used, P = 0.0305 (E and F). Survival analyses in 
(A), (B), and (D) were done via log-rank (Mantel-Cox) tests. 
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Figure 3.9: ITGB4 expression correlates with ITGA6, CD44, and EGFR in SCC. 
By linear regression, ITGB4 mRNA expression levels were positively correlated with 
ITGA6 (A), CD44 (B), and EGFR (C).
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Figure 3.10: Network map illustrating highly altered genes associated with ITGB4. 
In this network map generated using cBioPortal, ITGB4 is connected to laminins 
(LAMC2, LAMA1, LAMB1, LAMA2, etc), genes in the EGFR family (EGFR, ERBB3),
genes in the PI3K pathway (PIK3CA, AKT1), other integrins (ITGA6, ITGB1) and the 
tetraspanin CD151.
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Discussion 
In this study, I found that integrin β4 is highly expressed in lung SCC, and that its 
overexpression is associated with venous invasion and reduced overall survival in 
patients with NSCLC. These results are in accordance with findings in other cancers that 
demonstrate an association between integrin β4 overexpression and poor 
prognosis.50,100,109 Previous studies have demonstrated that the integrin β4 is highly 
expressed in SCC, however, this is one of the first studies to demonstrate that it has 
prognostic significance. Early reports have shown that expression of the integrin α6β4 
(previously described as TSP-18084) is elevated in murine Lewis lung carcinoma variants 
with high metastatic potential.154,155 As mentioned previously, integrin β4 has been 
shown to form a complex with and to amplify ErbB-2 signaling, and notably, ErbB-2 and 
integrin α6β4 co-localization have been identified in the lung cancer cell line Calu-3.156
Multiple studies investigating integrin β4 expression in patient-derived tissues have 
shown that it is expressed in NSCLC, with high levels observed in squamous cell 
carcinomas.101-103 A more recent study using gene expression profiling identified 
differentially expressed genes in samples of pulmonary ADC, SCC, and normal 
bronchus.104 In this study, integrin β4 was found to be significantly upregulated in 
SCC.104 Notably, the integrin β4 gene (ITGB4) is upregulated in the basal molecular 
subtype of lung SCC as defined using unsupervised clustering of gene expression 
microarray data.157  
Tumor metastases are responsible for the majority of cancer related deaths.158 In 
order for cancer cells to metastasize, they must acquire access to the circulation through 
a process termed intravasation.159 Integrin β4 has been shown to enhance tumor cell 
binding to the vascular endothelium, and can also mediate vascular permeability through 
its effects on vascular endothelial growth factor (VEGF) expression.160,161 Notably, 
integrin β4 mediated signaling has been shown to enhance VEGF protein expression by 
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upregulating its cap-dependent translation.161 VEGF expression leads to the disruption 
of endothelial junctions, thus allowing tumor cells to enter the circulation where they can 
travel to distant sites, extravasate, and metastasize.160 We have shown that integrin β4 
overexpression is associated with venous invasion in NSCLC, and its effects on VEGF 
expression may be partially responsible for this phenomenon.  In addition, integrin β4 
has been shown to promote the expression of a number of pro-metastatic and pro-
invasive proteins including S100A4,35 which also contributes to its ability to promote 
vascular invasion and tumor metastases.  
In this study, expression of the integrin β4 gene was positively correlated with 
expression of the cancer stem cell maker, CD44.162 CD44 is a transmembrane 
glycoprotein that has been shown to facilitate many aspects of tumor progression and is 
important in promoting resistance to therapy.162-164 Interestingly, integrin β4 has been 
implicated in promoting stem cell like properties in breast cancer,165 and has been 
identified in the cancer stem cell population in NSCLC.166 Integrin β4 gene expression 
was found to positively correlate with expression of EGFR, and in the network map, 
integrin β4 was connected to genes in the EGFR signaling pathway. These findings are 
notable in light of evidence demonstrating a functional relationship between EGFR and 
integrin β4.7,167 In particular, integrin β4 has been shown to interact with EGFR in lipid 
rafts where it enhances cell growth and proliferation.40 Furthermore, our lab has 
demonstrated that in pancreatic cancer, integrin α6β4 promotes autocrine EGFR 
signaling (unpublished data).  In the network map, integrin β4 was connected to a 
number of laminins (LAMA3, LAMC2, LAMB4), which is consistent with the fact that 
integrin β4 binds laminins in the extracellular matrix.  Also notable was the connection 
between integrin β4 and COL17A1, (Collagen, Type XVII, Alpha 1), as this gene 
encodes the BP180 protein that is necessary for hemidesmosome assembly. Finally, 
expression of integrin β4 gene was correlated with that of its binding partner, integrin α6. 
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In summary, I have demonstrated that integrin β4 is elevated in NSCLCs 
compared to normal lung tissue, and that it is overexpressed in lung SCC. Furthermore, 
a positive association was demonstrated between the presence of venous invasion and 
integrin β4 overexpression. Integrin β4 overexpression was associated with reduced 
overall survival in patients included in the TMA, as well as in external cohorts. While 
difficult to quantify on tissue microarray sections, integrin β4 expression was noted to be 
elevated at the invasive front of numerous tumors.   
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CHAPTER 4: α6β4 
Gliomas account for 30% of all primary tumors of the central nervous system (CNS) 
and represent about 80% of malignant CNS tumors.168 In adults, this class of tumors 
tends to have a poor prognosis, with 5-year survival rates for high-grade gliomas ranging 
from 4%-52%.168 Glioblastoma multiforme (GBM) accounts for over 50% of gliomas and 
carries an extremely poor prognosis, with a median survival of around only 14 months 
even when treating with temozolomide and radiation therapy.169 A key reason for this 
dismal prognosis is the diffusely infiltrative nature of these tumors, which renders 
complete surgical excision impossible. 
Tumors of the central nervous system can be classified into four categories using 
criteria developed by the World Health Organization (WHO). These categories include 
tumors that range from those with low proliferative potential (Grade I) to tumors that are 
cytologically malignant and display increased mitotic activity and areas of necrosis 
(Grade IV).170 This histologic grading system provides a mechanism that can assist with 
the prediction of biologic behavior and response to therapy.  
Mutations in isocitrate dehydrogenases types 1 and 2 (IDH1/2) have been 
identified in a number of human malignancies, including gliomas, chondroid tumors, and 
acute myeloid leukemia (AML).171-174 These mutations are present in the majority of 
WHO grade II and III gliomas, and are also characteristic of secondary GBMs.174-177
Both enzymes normally oxidize isocitrate to alpha-ketoglutarate, but point mutations at 
R132 in IDH1 or R172 in IDH2 produce neoenzymatic activity, reducing alpha-
ketoglutarate to D-2-hydroxyglutarate (2-HG).178,179 2-HG may contribute to 
gliomagenesis by promoting histone and DNA hypermethylation and suppressing cellular 
differentiation.180 Although IDH1/2 mutations have been shown to contribute to 
gliomagenesis, they do not appear to be sufficient for tumor induction.181,182 It is likely 
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that IDH1/2 mutations are early events in gliomagenesis that, when coupled with either 
TP53 or 1p/19q co-deletion, can lead to tumor development.181,183 In particular, these 
mutations are powerful favorable prognostic markers, though the reasons for this have 
not been fully elucidated.181  
Expression of the integrin β4 subunit has not been extensively studied in gliomas, 
and it is not known whether integrin β4 has clinical or prognostic significance in these 
tumors. Furthermore, the effect of IDH1 mutations on the expression of cellular adhesion 
molecules such as the integrin β4 is unknown. We therefore investigated integrin β4 
expression in a cohort of grade II-IV gliomas with and without IDH1 mutations, integrated 
results with outcome, and evaluated the effect of R132H IDH1 overexpression on 
integrin α6β4 levels in human glioma cells. Here, we report that integrin α6β4 is 
associated with progression and reduced overall survival in diffuse gliomas and is 
inversely correlated with mutant IDH1 status, potentially identifying a factor contributing 
to the more favorable prognosis associated with mutant IDH1. 
Materials and Methods:
Formalin-fixed, paraffin-embedded (FFPE) glioma tissues were retrieved from the 
pathology archives at the University of Kentucky. Deidentified tissue microarrays (TMAs) 
were constructed from the gliomas as previously described.184 A total of 104 cases 
comprised the TMAs, including 9 nonneoplastic controls (cortical dysplasia), 9 grade II 
astrocytomas, 11 grade III astrocytomas, 12 anaplastic oligodendrogliomas, 16 grade II 
oligodendrogliomas, and 47 grade IV GBMs. Treatment and outcomes were obtained via 
the Kentucky Cancer Registry. Institutional Review Board approval was obtained prior to 
collecting the archival tissues for TMA construction and patient retrieval data. 
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Immunohistochemistry
Immunohistochemistry for the integrin β4 subunit was performed as described in 
Chapter 2. Specifically, the primary antibody was used at 1:100 and the secondary 
antibody was used at 1:500. Integrin β4 expression was scored using a semiquantitative 
scale as follows: negative (0), minimal staining (1), weakly positive (2), moderately 
positive (3), strongly and diffusely positive (4). Endothelial cells were used as internal 
positive controls while non-neoplastic tissue cores served as negative controls. Scoring
was done while blinded to WHO grade and IDH1 mutation status. Results from all three 
tissue cores were averaged together to produce a final score for each tumor.  
R132H IDH1 immunohistochemistry of TMAs was performed as previously 
described.184 Of note, 5 TMA cases were immunonegative for R132H IDH1 but were still 
suspected of having a less common IDH1 or IDH2 mutation based on mutation-
associated variables like WHO grade and younger patient age. Of those 5, a single 
anaplastic astrocytoma turned out to have R132S IDH1 via pyrosequencing. 
Pyrosequencing was performed in the Molecular Pathology Department at the University 
of Kentucky according to a clinically validated protocol.   
Immunoblotting
LN18-GFP, LN18-GFP WT IDH1 and LN18-GFP IDH1 mutant cell lines were 
generated as previously described.184 Cells were harvested in RIPA buffer (150 mM 
NaCl, 0.5 mM EGTA, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 50 mM 
Tris-HCl pH 7.4, 15 μg/ml protease inhibitor cocktail, 1 mM PMSF). Total cell lysates (80 
μg) were subjected to 8% SDS-PAGE, transferred and immunoblotted with mouse anti-
human integrin β4 antibody (clone 7/CD104; BD Bioscience, San Jose, CA). β-actin was 
used as the loading control. Immunoblotting was performed by Min Chen, MD, PhD.  
56 
Bioinformatics analysis of external cohorts 
To validate TMA data with external cohorts, the relationship of integrin β4 to tumor 
type and GBM patient survival was done using the Oncomine microarray database 
(Oncomine, Compendia Bioscience, Ann Arbor, MI http://www.oncomine.org). Specific 
correlations between ITGB4 mRNA and IDH1 status, or ITGB4 mRNA and other 
mRNAs, were done via direct query of The Cancer Genome Atlas (TCGA Research 
Network, http://cancergenome.nih.gov/). Additional survival data in a separate cohort of 
GBMs was obtained via the National Cancer Institute REpository for Molecular BRAin 
Neoplasia DaTa (REMBRANDT, https://caintegrator.nci.nih.gov/rembrandt/).
Results
To determine the range of integrin α6β4 expression in gliomas, 
immunohistochemistry for the β4 subunit was performed on a set of glioma TMA blocks 
from 104 cases (see Materials and Methods). Integrin β4 expression was uniformly weak 
in nonneoplastic control tissues, but showed a greater range of staining intensities in 
grades II-III gliomas (Figs. 4.1 and 4.2A). However, the overall mean intensity was 
significantly greater only in grade IV GBMs (Fig. 4.2A; P < 0.0001). After adjusting for 
WHO grade, no significant difference in β4 expression was seen between astrocytic and 
oligodendroglial tumors (Fig. 4.3A). External cohorts confirmed this association, showing 
elevated ITGB4 mRNA in GBMs compared to nonneoplastic brain (Figs. 4.2B and 4.3B).
Patient-derived nonneoplastic neural progenitor cells also showed significantly lower 
ITGB4 mRNA in vitro compared to primary patient-derived GBM cells and some other 
commonly-used GBM cell lines (Fig. 4.3C).
In carcinomas, integrin β4 is known to promote more invasive and aggressive 
behaviors50,53,72,86,99,105,110 and has been shown to upregulate S100A4,172 a gene 
encoding for a pro-metastatic protein that is involved in the epithelial to mesenchymal 
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transition.185 Gene expression profiling has identified multiple molecular subtypes of 
GBM, including a mesenchymal phenotype.186 In the TCGA set of GBMs, increasing 
levels of ITGB4 mRNA correlate with increasing levels of CHI3L1 and S100A4 (P <
0.0001), both of which are robust mesenchymal markers (Fig. 4.4A-B), and average 
ITGB4 mRNA levels were the highest in the mesenchymal sub-type of GBMs (Fig. 
4.4C).  
Mutant IDH1 has been shown to be a strong favorable prognostic factor in diffusely 
infiltrative gliomas,181 and high integrin β4 expression can contribute to cancer 
invasiveness and aggression.50,53,72,86,99,105,110  Interestingly, a strong inverse relationship 
between IDH1 mutations and integrin β4 expression was observed in our TMA cohort (P
< 0.0001) (Figs. 4.5 and 4.6A-B). Likewise, TCGA GBMs that had IDH1 mutations 
showed lower ITGB4 mRNA levels than IDH1 wild-type tumors (P = 0.005) (Fig. 4.6C). 
In the TCGA, IDH1-mutant GBMs also showed a slight increase in ITGB4 promoter 
methylation (P = 0.0008) (Fig. 4.6D). To test whether IDH1 mutations can drive the 
reduction in integrin β4 expression, we analyzed LN18 GBM cells overexpressing either 
wild-type IDH1 or R132H IDH1 mutant. We found that R132H IDH1 overexpression 
downregulated integrin β4 protein levels compared to either the control vector 
transfected or wild-type IDH1 expressing cells (P < 0.0001) (Figs. 4.6E-F). These data 
suggest that mutant IDH may suppress integrin β4.
To date, no data on integrin β4 and outcome in gliomas has been published. In our 
TMA cohort, high integrin β4 expression significantly associated with shorter overall 
survival (OS) in all grade II-IV gliomas (median survival not reached for integrin β4 IHC 
score < 1; 63.5 months for 1-1.9; 18.1 months for 2+, P = 0.0005) (Fig. 4.7A), as well as 
when considering only high-grade (III-IV) gliomas (30.7 months for integrin β4 IHC score 
<2; 17.8 months for 2+, P = 0.02) (Fig. 4.7B). When focusing only on GBMs, however, 
no significant difference was seen (10.9 months for integrin β4 IHC score <2; 9.3 months 
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for 2+, P = 0.97). However, in both the TCGA and NCI Rembrandt GBM datasets, 
increasing levels of ITGB4 mRNA correlated with worse OS (Figs. 4.7C-D) This 
indicates that integrin β4 may have an effect on outcome in GBMs as has been seen in 
other cancers, but that larger cohorts are needed to demonstrate this. Moreover, in our 
TMA cohort, integrin β4 was not an independent prognostic factor when including 
variables like WHO grade and IDH1 status (Table 4.1).  
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Figure 4.1: Integrin β4 expression in gliomas. Average integrin β4 levels are 
significantly increased in grade IV GBMs compared to nonneoplastic brain tissues and 
grade II and III gliomas. The inset in the grade IV integrin panel highlights membranous 
staining of integrin β4 in GBM cells (arrowheads). Magnification = 400x for all images.
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Figure 4.2: Integrin β4 expression is higher in grade IV GBMs than lower grades of 
gliomas. (A) GBMs had a higher level of integrin β4 expression than lower grade tumors 
and nonneoplastic brain tissue, as measured by semiquantitative immunohistochemistry. 
No significant differences were seen between grades II and III gliomas, or between II-III 
gliomas and nonneoplastic tissue. Overall P < 0.0001 via one-way ANOVA, *P < .0001 
between grade IV GBMs and each other group via post-hoc Tukey’s test. (B) Likewise, 
TCGA GBMs showed greater average levels of ITGB4 mRNA than nonneoplastic brain. 
P = 0.01 via two-tailed t-test.  
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Figure 4.3: Integrin β4 expression by glioma histotype and cell lines. (A) There was 
no significant difference between mean integrin β4 IHC scores among astrocytomas 
(astro) or oligodendrogliomas (oligo), either at the grade II level or grade III level. P =
0.51 via one-way ANOVA. (B) In the Bredel 2 glioma cohort obtained through Oncomine 
(see Methods), there was a strong trend toward higher ITGB4 mRNA in GBMs versus 
nonneoplastic control brain and grades II-III gliomas (P = 0.05 via one-way ANOVA). (C) 
In the Lee data obtained through Oncomine (see Methods), nonneoplastic human neural 
progenitor cells (NPCs) had lower ITGB4 mRNA compared to primary cultures of 
patient-derived GBMs and three GBM cell lines: U373 MG, U251, and U387. Overall P <
0.0001 via one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001 via post-hoc Tukey’s 
test. For the sake of simplicity, other statistically significant differences that were found 
(e.g. between U373 MG and U188 MG) are not shown. Data in this figure analyzed by 
Craig Horbinski, MD, PhD.  
62 
Figure 4.4: Integrin β4 expression correlates with mesenchymal markers in TCGA 
GBM dataset. By linear regression, ITGB4 mRNA positively correlates with 
mesenchymal markers CHI3L1 (A) and S100A4 (B) in TCGA GBMs. N = 424. (C) By 
GBM expression subtype, average ITGB4 mRNA levels were the highest in 
mesenchymal GBMs, with proneural tumors showing the lowest ITGB4 levels. Overall P 
< 0.0001, *P < 0.05, **P < 0.01, ***P < 0.001. N = 434. . Data in this figure analyzed by 
Craig Horbinski, MD, PhD.  
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Figure 4.5: Integrin β4 immunoreactivity in IDH1-mutant versus wild type gliomas. 
Compared to a grade IV GBM that is wild-type for IDH1 (left panels), a GBM with R132H 
IDH1 has less intense integrin β4 staining (right panels). Magnification = 400x for all 
images. 
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Figure 4.6: Integrin β4 expression is lower in IDH1-mutant gliomas. Tumors with 
mutant IDH1 showed significantly less integrin β4 expression via immunohistochemistry, 
either by pooling all grade II-III gliomas together (A) or by focusing only on high-grade (III 
& IV) gliomas (B). Likewise, IDH1-mutant GBMs from the TCGA had lower levels of 
ITGB4 mRNA compared to wild-type GBMs (C) and tended to have more methylation of 
cg23913400, a CpG island in the ITGB4 promoter (D). Overexpression of R132H IDH1 
markedly downregulated integrin β4 in LN18 glioma cells (E), densitometric data from 5 
independent blots were combined and quantified in (F). Statistical analyses in (A-D) 
were done via two-tailed t-tests; (F) was done via one-way ANOVA. *P < 0.05 versus 
vector, **P < 0.001 versus vector and wtIDH1 as determined by post hoc Tukey’s test. 
Data in E and F generated by Min Chen, MD, PhD. 
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Figure 4.7: Integrin β4 and survival in gliomas. When pooling all gliomas together 
(A), increased expression of integrin β4 (categorized by the semiquantitative data as 
shown in Figures 1 and 2A) correlated with shorter median OS. *P = 0.004 versus 1-1.9 
and *P = 0.0003 versus < 1. There was no significant difference between < 1 and 1-1.9 
(P = 0.14). Even when focusing on just high-grade (III & IV) gliomas (B), expression 
levels of 2 or more still correlated with worse OS, P = 0.02. (C) In TCGA GBMs, 
increasing ITGB4 mRNA levels significantly correlated with decreased proportion of 
patients surviving 5 years. Overall P = 0.002 via Kruskal-Wallis test; post-hoc values 
were derived via Dunn’s multiple comparison test. (D) In the NCI Rembrandt dataset, 
GBMs with upregulation of ITGB4 mRNA (as defined by > 3-fold increased mRNA levels 
compared to nonneoplastic control tissue) had a 30% shorter median survival compared 
to GBMs with less than threefold increase in ITGB4 mRNA (13.2 versus 17.1 months). 
Survival analyses in (A), (B), and (D) were done via log-rank (Mantel-Cox) tests.  
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Table 4.1: Multivariate survival analysis of gliomas. Via Cox proportional hazards 
survival regression (N = 88), significant independent prognostic factors included high 
WHO grade, IDH1 mutations, adjuvant radiation, and adjuvant temozolomide (TMZ), but 
not integrin β4 expression (2+ versus < 2 as described in Figures 1 and 2). All tumors 
underwent extensive resection, not just biopsy. Multivariate analysis performed by Craig 
Horbinski, MD, PhD.  
Variable Relative risk 95% CI P
integrin β4 moderate to high 1.3 0.61—2.6 0.55
grade III-IV vs II 21.3 4.4—104.6 0.0002
age < 45 years 0.81 0.41—1.6 0.55
astrocytic morphology 1.3 0.48—3.4 0.62
IDH1 status 0.21 0.069—0.63 0.0052
adjuvant radiation 0.42 0.19—0.91 0.029
adjuvant TMZ 0.32 0.16—0.67 0.0023
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Discussion
The results of this study demonstrate that integrin β4 is highly expressed in GBMs 
compared to lower grade gliomas and non-neoplastic tissue. We found that high integrin 
β4 expression is an adverse prognostic marker, which is consistent with work done in 
other cancers showing that integrin α6β4 overexpression imparts more aggressive, 
invasive behavior.50,53,72,86,99,105,110  We also found that integrin β4 was significantly lower 
in tumors with IDH1 mutations, which was confirmed in external gene expression 
databases, and that overexpressing R132H IDH1 sharply suppresses integrin β4 
expression in glioma cells. This may help explain why IDH1/2-mutant gliomas tend to be 
less aggressive than their wild-type counterparts.187,188
To date, very few papers have been published on the subject of integrin α6β4 in 
gliomas. Prior work has shown that integrin β4 expression in gliomas is variable, though 
these studies examined smaller numbers of patient-derived glioma tissues. Previtali et 
al.126 found that the integrin β4 expression is present in reactive astrocytes, and that 
expression is elevated in astrocytomas. A larger study investigated expression of the β4 
subunit in a series of astrocytomas and oligodendrogliomas, and found that β4 
expression was slightly higher in oligodendrogliomas.128 Previtali et al189 found that the 
α6β4 integrin was diffusely expressed in both neoplastic and reactive astrocytes in an 
animal model of ethylnitrosourea (ENU) induced glioblastoma. Interestingly, they 
describe that β4 staining was identified early in tumor development, and that staining 
was more intense within the neoplastic cells of proliferative centers.189 Integrin β4 
expression has been identified in multiple astrocytoma cell lines (SF-767, NCE G-22 and 
NCE G-112) by RT-PCR,190 and was identified in the oligodendroglial cell line HS-683.128
More recently, a study was published describing the interaction between the β4 integrin 
and netrin-4 (NTN4) in glioblastoma progression.191 The current study is the first to 
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show that integrin α6β4 is higher in GBMs than lower-grade gliomas, that it is an 
adverse prognostic marker, and that mutant IDH1 suppresses its expression. 
Within GBMs, integrin β4 had no prognostic significance in the TMA cohort, 
although it did in external GBM databases (Figure 5). This is likely due to the fact that 
the external cohorts were larger. Moreover, integrin β4 was not an independent 
prognostic marker on multivariate analysis (Table 1), which may be due to the fact that 
integrin β4 is so tightly correlated with IDH1 mutation status and tumor grade (Figures 2-
4). Thus, it is very unlikely that lower integrin β4 expression is the sole reason why 
mutant IDH1 is a positive biomarker, but rather that it contributes to the overall favorable 
prognosis in such tumors. For example, mutant IDH1 also leads to MGMT promoter 
hypermethylation, thus reducing the ability of the tumor to repair DNA damage done by 
alkylating chemotherapeutic agents. It is therefore not surprising that a mutation that 
triggers global hypermethylation would accidently make a few changes that are 
somewhat deleterious to the tumor.181 Epigenetic regulation of integrin β4 through 
promoter hypermethylation and histone modification has been previously described.192
Whether hypermethylation is the mechanism by which mutant IDH1 suppresses integrin 
β4 mRNA and protein expression is the subject of ongoing research. 
The role of integrins in glioma development and progression is a growing 
component of neurooncology research. For example, integrin α6 is a marker for GBM 
stem cells, and its interaction with laminin α2 in the extracellular matrix is an important 
mediator of stem cell properties like self-renewal and tumor formation.193,194 Integrin ß8 is 
also expressed in gliomas, positively correlates with overexpression of EGFR and 
PDGFRA, and may promote FAK and ERK activity in regions rich in extracellular 
matrix.195 The αvβ3 and αvβ5 integrins have been implicated in tumor-induced 
angiogenesis,196 which is a common feature of GBMs.197 The αvβ3 and αvβ5 integrins 
increase with increasing histologic grade in gliomas, and tumor cells at the periphery of 
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high-grade gliomas have higher αvβ3 expression.198 Attempts to target αvβ3 and αvβ5 in 
GBM led to multiple clinical trials with cilengitide, a small molecule inhibitor of the αvβ3, 
αvβ5 and α5β1 integrins.199 While a phase II clinical trial (NABTT 0306) demonstrated a 
modest improvement in median survival for patients treated with cilengitide, further 
studies in patients with newly diagnosed GBM have not been successful.169,200
In summary, we have demonstrated that expression of the β4 integrin is decreased 
in tumors with mutations in IDH1, which we confirmed using a glioma tissue microarray, 
gene expression databases, and overexpression of R132H IDH1 in vitro. This study is 
the first to demonstrate that mutant IDH1 can decrease the expression of a cell adhesion 
molecule. Further work is needed to clarify the mechanism(s) by which mutant IDH1 
alters the expression of cellular adhesion molecules, and to examine the role of integrin 
α6β4 in gliomagenesis and invasion. Gaining a deeper understanding of why mutant 
IDH1 gliomas are less aggressive than their wild-type counterparts will not only help 
develop ways of targeting IDH1-mutant gliomas, but also of making wild-type tumors 
behave more like mutant tumors.  
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CHAPTER FIVE: INTEGRIN α6β4 EXPRESSION IN NORMAL AND NEOPLASTIC 
BREAST 
Breast cancer is the most common cancer diagnosed among women in the 
United States, and is also a leading cause of cancer related death among women in this 
country.132 Breast cancer is responsible for over 40,000 deaths annually, and incidence 
continues to rise.132 It is now estimated that 1 in 8 women will be diagnosed with breast 
cancer during their lifetime.132 While advances in clinical care have resulted in improved 
survival for many women with breast cancer, there are still subtypes that carry a poor 
prognosis and remain difficult to treat effectively. Importantly, breast cancer does not 
represent one disease, but instead represents a number of different disease processes, 
all with unique morphologies and molecular phenotypes.   
From a clinical perspective, breast cancer can be divided into three main 
categories: hormone receptor positive, HER2 positive, and triple negative. These clinical 
subtypes of breast cancer are defined by expression of the estrogen receptor,
progesterone receptor, and HER2 (ERBB2). Assessment of these three markers is 
routine in clinical practice. While expression of ER and PR are assessed using 
immunohistochemistry, HER2 expression can be assessed using immunohistochemistry, 
fluorescence in situ hybridization (FISH), or chromogenic in situ hybridization (CISH). 
Hormone receptor positive tumors generally express the estrogen receptor (ER) and 
have variable expression of the progesterone receptor (PR). Patients whose tumors are 
hormone receptor positive are generally candidates for therapy with hormone receptor 
antagonists, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and
drugs that suppress ovarian function.  Patients with amplification or overexpression of 
HER2 can now be treated with a wide array of anti-HER2 therapies including monoclonal 
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antibodies such as trastuzumab and tyrosine kinase inhibitors such as Lapatinib. While 
these advances have significantly improved the survival of patients with breast cancer, 
triple negative tumors lack expression of ER, PR, and HER2, and so are not amenable 
to treatment with the therapies described above. Patients with TNBC tend to have 
reduced survival when compared to patients with hormone receptor positive or HER2 
amplified disease.201,202  
The clinical classification of breast cancer based on expression of ER, PR, and 
HER2 helps to inform and streamline clinical decision making, however, it does not 
reflect the true heterogeneity of this disease. The WHO histologic classification of breast 
tumors recognizes at least 37 different entities, not including primary mesenchymal and 
lymphoid neoplasms of the breast.203 The epithelial subtypes of breast cancer range 
from commonly encountered tumors such as invasive ductal, lobular, and tubular 
carcinomas to rare entities including adenoid cystic carcinoma, secretory carcinoma, and 
glycogen-rich clear cell carcinoma. While pathologists have long recognized these 
diverse histologic subtypes, recent studies using molecular profiling have uncovered 
specific subtypes that are based on differences in gene expression, mutation profile,
copy number alterations, and epigenetic modifications. One of the more widely accepted
classification schemes divides breast cancer into four main molecular subytpes: Luminal 
A, Luminal B, HER2 and basal-like.70,204,205  
Luminal A breast cancers are characterized by elevated mRNA expression of 
genes such as ESR1, GATA3, FOXA1, XBP1, and by mutations in PIK3CA, GATA3 and 
FOXA1.70 Luminal A tumors tend to express both ER and PR, and so are amenable to 
treatment with estrogen receptor modulating agents. These tumors have the best 
prognosis out of the molecular subtypes. Luminal B tumors are characterized by a higher 
proliferation index than Luminal A tumors, and by mutations in PIK3CA, GATA3, and 
TP53.70 The third molecular subtype is the HER2 enriched; clinically, these tumors tend 
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to have amplification and/or overexpression of HER2.  Mutations in PIK3CA and TP53
are common in HER2 enriched tumors. The final molecular subtype is the basal-like. 
Basal-like breast cancer tends to be triple negative, though the two categories are not 
mutually exclusive. Many, but not all, basal-like tumors are triple negative, though there 
are some exceptions. The basal-like subtype is marked by a high frequency of TP53
mutations, and loss of TP53 function is present in the vast majority of basal-like breast 
cancers.70 PIK3CA amplification and deletion of the tumor suppressors RB1 and PTEN
are also characteristic of basal-like breast cancers. These tumors tend to express basal 
cytokeratins such as CK5 and CK6, and also have elevated expression of genes 
associated with proliferation.70 Correspondingly, these tumors tend to be aggressive and 
highly proliferative, leading them to have the poorest prognosis of all breast cancer 
subtypes. Basal-like breast cancer is also common in African-American women and in 
young women, which partially explains the poor prognosis associated with these patient 
populations.  
Ductal carcinoma in situ (DCIS) is a pre-invasive neoplasm of the breast that 
accounts for up to 20% of newly diagnosed breast cancers.206 This neoplastic change 
takes place in the ductal epithelium, where a proliferation of cells fills and expands the 
ductal system. In order for a lesion to be classified as DCIS, the neoplastic cells must 
remain confined to the duct, without invasion through the basement membrane. Once 
neoplastic cells escape from the confines of the basement membrane and invade into 
the stroma, the lesion is termed invasive breast cancer. While pure DCIS has a better 
prognosis when compared to invasive breast cancer, it is a marker of increased risk for 
the development of subsequent invasive carcinoma, and when diagnosed on core 
needle biopsy, DCIS may be associated with the presence of an underlying invasive 
breast cancer. In particular, high-grade DCIS is associated with a worse clinical outcome 
and may be linked to the development of high-grade invasive breast cancer.207,208 It has 
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been shown that DCIS can be categorized into molecular subtypes similar to those 
identified in invasive breast carcinoma,209 and while low-grade DCIS is often positive for 
the hormone receptors estrogen and progesterone, high-grade DCIS is commonly 
hormone-receptor negative.206 DCIS has a variety of morphologic subtypes, many of 
which have distinct molecular profiles and clinical outcomes.209 Included among these 
subtypes are solid, cribriform, papillary, micropapillary, basal-like, apocrine and comedo-
type DCIS. A variety of clinical classification systems have been developed for DCIS, 
though consensus guidelines focus on the evaluation of nuclear grade.210 This system 
divides DCIS into low grade (grade 1), intermediate grade (grade 2), and high-grade 
(grade 3) based on features such as nuclear atypia and nuclear size.210 This grading 
scheme provides prognostic information, as high-grade DCIS is associated with an 
increased risk for the later development of invasive breast cancer.  
Materials and Methods
Breast Translational Group (BTG) TMA: 
Institutional Review Board Approval (13-0608-P2H) was obtained prior to 
initiating the project. Surgical resections for breast cancer performed at the University of 
Kentucky from January 1, 2000 to December 31, 2012 were identified using natural 
language searches in CoPath (Cerner Corporation, Kansas City, MO). A total of 343 
invasive breast cancers were selected for inclusion, including 165 TNBCs, 74 HER2 
positive tumors, and 104 hormone receptor positive tumors. Original hematoxylin and 
eosin (H&E) stained slides were reviewed and appropriate tumor blocks were selected 
from each case. Fresh H&E stained sections were then cut from each selected tumor 
block. These fresh sections were then reviewed and tumor areas were selected for 
inclusion in the TMA.  Pathologic features, treatment and outcome data were collected 
by the Cancer Research Informatics Shared Resource Facility and the Kentucky Cancer 
74 
Registry. Tissue core placement was randomized by the Biostatistics and Bioinformatics 
Shared Resource Facility. Three 2 mm diameter tissue cores were obtained from each 
tumor specimen, which were transferred to recipient paraffin blocks using a TMArrayer 
(Pathology Devices, Westminster, MD). The completed TMAs contained 1029 tissue 
cores spread over 15 blocks. TMA sections used for integrin β4 immunohistochemistry 
had interpretable tissue cores in 336/343 cases.  
DCIS and Benign Breast Tissue 
Institutional Review Board Approval (14-0236-P6H) was obtained prior to 
initiating the project. In order to identify cases of normal breast and DCIS, CoPath 
(Cerner Corporation, Kansas City, MO) was used to conduct natural language searches. 
Individual cases were then reviewed and appropriate cases were selected for inclusion. 
Benign breast tissue was obtained from leftover reduction mammoplasty cases, and 
patients were excluded from the benign category if they had a history of atypia, in situ 
disease, or invasive carcinoma. A total of 78 tissue blocks were identified, including 20 
benign breast samples, 16 cases of low-grade DCIS, 18 cases of intermediate-grade 
DCIS, and 24 cases of high-grade DCIS.  
India Breast TMA 
Breast cancers obtained from patients in India were used by the Markey 
Biospecimen and Tissue Procurement Shared Resource Facility to construct tissue 
microarrays by the method describe above. A total of 56 invasive breast cancers 
comprised the Indian Breast TMA.  
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Immunohistochemistry and TMA Scoring 
For BTG TMA sections, immunohistochemistry for the integrin β4 was performed 
according to the protocol described in Chapter 2. Specifically, the primary antibody was 
used at 1:200 and the secondary antibody was used at 1:500. Due to differences in 
tissue processing between this cohort and the India breast cancer cohort, sections from 
the India TMA were stained for the integrin β4 subunit using the protocol described in 
Chapter 2, but at a primary antibody concentration of 1:100 and a secondary antibody 
concentration of 1:500. Immunohistochemical staining for ER, PR, and HER2 was 
performed using the antibodies and protocols listed in Table 5.1 (Dako Corporation, 
Carpinteria, CA, USA). Integrin β4 expression was scored using a semiquantitative scale 
as follows: negative (0), minimal staining (1), weakly positive (2), moderately positive (3), 
strongly and diffusely positive (4). Scoring for ER, PR, and HER2 was performed 
according to guidelines published jointly by the College of American Pathologists (CAP) 
and the American Society for Clinical Oncology (ASCO).211,212 Results from each of the 
three tissue cores were averaged to produce a final score for each tumor. Scoring was 
performed by while blinded to clinical and pathologic data.   
76 
Table 5.1: Antibodies used for ER, PR, and HER2 immunostaining. 
Marker ER PR HER2 
Product ID IR08461-5 IR06861-5 A048529-1
AR Solution EnVision
FLEX Target  
Retrieval  Solution, 
High pH
EnVision
FLEX Target  
Retrieval  Solution, 
High pH
No AR per 
manufacturer’s 
specifications
AR Time 20 minutes 20 minutes N/A
AR Temperature 97° 97° N/A
1° Antibody Conc. Pre-diluted Pre-diluted 1:100
1° Incubation Time 25 minutes 25 minutes 20 minutes
2° Antibody Anti-rabbit 
(Envision+ kit)
Anti-mouse
(Envision+ kit)
Anti-rabbit
(Envision+ kit)
Detection Envision+ Envision+ Envision+
DAB Time 10 minutes 10 minutes 10 minutes
All reagents are from Dako Corporation. 
AR = Antigen retrieval.  
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Results 
Integrin β4 expression in benign breast and DCIS 
In benign breast tissue, integrin β4 was strongly expressed in myoepithelial cells, 
while staining in luminal epithelial cells was absent (Fig. 5.1A). This pattern was 
preserved in fibrocystic change and apocrine metaplasia (Fig. 5.1B). In usual ductal 
hyperplasia and columnar cell change without atypia, integrin β4 expression was limited 
to myoepithelial cells (data not shown). Microglandular adenosis is a benign proliferation 
that is believed to be a non-obligate precursor to invasive TNBC.213 Interestingly, integrin 
β4 expression was elevated in the single example of microglandular adenosis studied 
(Fig. 5.1B). Benign stroma, fibroblasts, adipose, and infiltrating lymphocytes were all 
negative for expression of the integrin β4 (Fig. 5.1). In benign breast tissue, endothelial 
cells and peripheral nerves had weak to moderate expression as has been previously 
described (Fig. 5.2).72
Expression of the integrin β4 in DCIS was variable. In some cases, integrin β4 
expression was present only in the residual myoepithelial cells lining DCIS (Fig. 5.3), 
whereas in other cases, integrin β4 expression was present in both neoplastic and 
myoepithelial cells. Within DCIS, integrin β4 expression was heterogeneous. There was 
a tendency for neoplastic cells in the outer layers of DCIS (adjacent to myoepithelial cell) 
to have elevated integrin β4 expression (Fig. 5.3). 
Integrin β4 in invasive breast cancer 
Integrin β4 expression in invasive breast cancer was also variable (Figs. 5.4 and 
5.6B-C). In some cases, infiltrating tumor cells exhibited strong and diffuse expression of 
the integrin β4, while others were completely negative for integrin β4 expression (Fig. 
5.4). In the India TMA cohort, we found that integrin β4 expression was elevated in 
TNBCs and HER2 positive breast cancers (Fig. 5.4). Although the number of HER2 
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positive tumors in this cohort was relatively small (N =14), integrin β4 overexpression 
was identified in the majority of these HER2 positive tumors (Fig. 5.5). In addition, 
integrin β4 overexpression was associated with high tumor grade in this cohort (Table 
5.2). An association was not identified between tumor size or the presence of lymph 
node metastasis in the India TMA cohort (Table 5.2).  
In the BTG TMA cohort, low-grade breast cancers such as tubular and cribriform 
carcinoma had low to absent expression of the integrin β4 (Fig. 5.6B). In the few tumors 
examined with residual benign ductal epithelium, integrin β4 was still present in 
myoepithelial cells surrounding the ducts (Figs. 5.6B and 5.7). In high-grade breast 
cancers, integrin β4 was expressed strongly and diffusely throughout infiltrating tumors 
cells (Fig. 5.6C). Integrin β4 expression was elevated in TNBCs and HER2 positive 
tumors when compared to hormone receptor positive breast cancers, with the highest 
levels of integrin β4 expression observed in TNBCs (Fig. 5.8A). Furthermore, integrin β4 
expression was associated with high tumor grade in the BTG TMA cohort (Fig. 5.8B).  
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Figure 5.1: Integrin β4 expression in benign breast. Integrin β4 expression in benign 
breast with fibrocystic change (A). Integrin β4 is absent in cells with apocrine metaplasia 
(center lesion), however, expression is elevated in adjacent benign microglandular 
adenosis (B).  
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Figure 5.2: Integrin β4 expression in endothelial cells and peripheral nerve. In a 
medium sized vessel, integrin β4 is expressed in endothelial cells lining the lumen (A). 
and is also expressed in peripheral nerves (B).  
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Figure 5.3: Integrin β4 
expression in DCIS. Low grade 
DCIS with integrin β4 
expression in myoepithelial cells 
surrounding neoplastic duct (A). 
Intermediate grade DCIS with 
elevated integrin β4 expression 
in myoepithelial and neoplastic 
cells (B). All images = 200x. 
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Figure 5.4: Integrin β4 expression patterns in clinical breast cancer subtypes. In 
the India TMA cohort, integrin β4 levels were significantly higher in triple negative and 
HER2 positive tumors. Paraffin-embedded breast cancer tissues were stained with 
antibodies to the integrin β4 subunit, ER, PR, and HER2. Representative images of triple 
negative, hormone receptor positive, and HER2 overexpressing tumors are shown.  
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Figure 5.5: Integrin β4 expression is elevated in HER2 positive tumors. Integrin β4 
expression was elevated in a subset of HER2 positive tumors in the India TMA. Panels 
A-D each show an example of a tumor stained for ER, PR, HER2 and integrin β4.
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Table 5.2: Integrin β4 expression and clinicopathologic features in breast cancer. 
β4 High β4 Low 
(n= 23) (n=31) 
Average tumor size 3.99 cm 3.91 cm 
P = 0.8617
Nodal disease 
Positive 17/40 (42.5%) 23/40 (57.5%) 
Negative 6/14   (43%) 8/14   (57%) 
P = 1.000
Tumor Grade 
II 2/15   (13%) 13/15 (87%) 
III 21/39 (54%) 18/39 (46%) 
P = 0.0125 
HER2 status 
Positive 10/14 (71%) 4/14   (29%) 
Negative 13/39 (33%) 26/39 (66%) 
P = 0.0259
Subtype 
Triple negative 7/10    (70%) 3/10   (30%) 
Hormone receptor + 8/34    (24%) 26/34 (76%) 
P = 0.0187 
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Figure 5.6: Examples of integrin β4 staining in the BTG TMA. 
The top panel demonstrates integrin β4 expression in benign ductal epithelium. The 
myoepithelial cells display strong staining for the integrin β4, whereas luminal epithelial 
cells are negative for integrin β4 expression (A). In this low grade invasive breast cancer, 
integrin β4 remains positive in the myoepithelial cells of benign ducts, but is absent in 
adjacent invasive carcinoma (B). In this high-grade invasive breast cancer, integrin β4 is 
strongly and diffusely expressed (C).  
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Figure 5.7: Example of integrin β4 relocalization. In the benign ducts and lobules 
(right) integrin β4 is highly expressed in myoepithelial cells, and at the basal aspect of 
luminal cells. In the invasive carcinoma (left), integrin β4 expression appears reduced, 
however, this relocalization of integrin β4 may be clinically significant due to a change in 
β4 signaling after release from hemidesmosomes. 
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Figure 5.8: Elevated integrin β4 expression is associated with clinical subtype and 
tumor grade. In the BTG TMA, integrin β4 levels were higher in triple negative and 
HER2+ breast cancers when compared to hormone receptor positive (HR+) breast 
cancers, P < 0.0001 via Kruskal-Wallis test with Dunn's Multiple Comparison Test (A). 
Average integrin β4 levels were also elevated in high-grade breast cancer, P = 0.0001 
(B).  
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In this study, I examined integrin β4 expression in invasive breast cancers from 
390 patients. This is the largest study to date of integrin β4 protein expression in human 
breast cancer.  Here, I found that integrin β4 is highly expressed in basal-like and HER2 
positive tumors, and that it associates with tumor grade. Furthermore, I characterized 
integrin β4 staining patterns in benign breast, where I found that expression is absent in 
the luminal cells of benign breast tissue, but is strongly expressed in the myoepithelial 
cells surrounding benign ducts. 
A major finding of this study is that integrin β4 expression is elevated in HER2 
positive tumors. Early studies demonstrated that integrin β4 expression correlates with 
HER2 expression in breast carcinoma cell lines,30,49 and furthermore, the integrin β4 
subunit has been shown to form a complex with HER2 that can amplify HER2 
signaling.27 However, in patient-derived tissues, the relationship between integrin β4 and 
HER2 expression is controversial.50-53 The Mercurio group analyzed breast cancer gene 
expression datasets using linear regression but did not find a positive correlation 
between ITGB4 and HER2 mRNA expression.50 The same group also analyzed patient-
derived tumors using immunohistochemistry, but again was unable to demonstrate a 
relationship between integrin β4 and HER2 protein expression.50 I analyzed expression 
of the integrin β4 in 72 HER2 positive tumors from two different patient cohorts where I 
found that integrin β4 levels were elevated in HER2 positive tumors when compared to 
hormone receptor positive tumors. While these data provide further evidence for a 
possible relationship between HER2 and integrin β4, study of additional cohorts will be 
necessary to make a definitive determination.   
A second important finding in this study is that integrin β4 expression is elevated 
in TNBCs. TNBC is the most aggressive breast cancer subtype and it carries a 
particularly poor prognosis. In this study, integrin β4 expression levels were highest in 
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TNBC. This observation may be partially explained by the fact that many TNBCs are 
immunohistochemically and phenotypically similar to myoepithelial cells, which have 
very high expression of the integrin β4.  The finding that integrin β4 is highly expressed 
in TNBC is not surprising given its association with other high-grade, aggressive cancers 
such as lung SCC (Chapter 3) and glioblastoma (Chapter 4).  
Microglandular adenosis is a rare but benign breast lesion that is characterized 
by a proliferation of small glands infiltrating through the stroma.214 This lesion can be 
mistaken for invasive breast cancer due to its infiltrative appearance and because it 
often produces a mass.214 We identified an incidental case of microglandular adenosis in 
the BTG TMA, and interestingly, the infiltrating glands were strongly and diffusely 
positive for expression of the integrin β4. Recently, a number of studies have suggested 
that microglandular adenosis may be a precursor lesion to invasive TNBC. Specifically, 
one group identified a pattern of recurrent gains and losses (2q+, 5q-, 8q+, and 14q-) in 
microglandular adenosis which is similar to that observed in basal-like breast cancer.215
Further investigation will be needed to determine whether integrin β4 plays a role in 
microglandular adenosis and the transition to invasive breast cancer. 
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CHAPTER SIX: SUMMARY AND FUTURE DIRECTIONS
Summary 
The purpose of this study was to examine integrin α6β4 expression as it relates 
to clinical variables and patient outcomes in aggressive human malignancies.  The 
hypothesis of this study was that in tumors of the lung, breast, and central nervous 
system, integrin β4 overexpression associates with aggressive behavior and reduced 
survival. In order to study integrin α6β4 protein expression in patient-derived tumors, 
tissue microarrays were constructed and sections were stained using 
immunohistochemistry for the integrin β4 subunit. Integrin β4 mRNA levels in patient-
derived tumors were also examined using external gene expression datasets. I found 
that integrin β4 expression was elevated in a subset of NSCLCs, and that 
overexpression associated with pathologic features. Specifically, integrin β4 was highly 
expressed in squamous cell carcinoma, and overexpression associated with venous 
invasion. Elevated integrin β4 protein and mRNA expression were also associated with 
decreased overall survival in patients with NSCLC. In gliomas, integrin β4 
overexpression was associated with tumor grade, and was also an adverse prognostic 
marker.  Furthermore, integrin β4 expression was reduced in gliomas with mutations in 
IDH1, thus partially explaining the better prognosis observed for IDH1 mutant tumors. In 
breast cancer, integrin β4 expression was found to be highest in triple negative tumors, 
and elevated integrin β4 expression was associated with HER2 overexpression and
tumor grade. In summary, I have shown that integrin β4 expression is elevated in a 
number of human malignancies, and that its expression associates with tumor 
aggressiveness and patient prognosis. 
91 
Future Directions 
Integrins have been the target of a variety of therapeutic agents, and notably, 
abciximab, eptifibatide and tirofiban, all of which target the integrin αIIbβ3, are important 
anti-platelet agents in clinical use.216 Thus far, attempts at targeting integrins in cancer 
have been less successful, though cilengitide, an inhibitor of the αvβ3, αvβ5 and α5β1 
integrins demonstrated modest success in early clinical trials.199,200,217 The αvβ3 and 
αvβ5 integrins have been implicated in tumor-induced angiogenesis, an important 
mechanism of tumor growth and survival.196 Results of a phase II trial of cilengitide 
combined with chemoradiation therapy in patients with the brain tumor glioblastoma 
(NABTT 0306) demonstrated a modest improvement in median survival (19.7 months) 
when compared to patients in the EORTC trial of temozolomide and radiation therapy 
(14.6 months).169,200 In addition, a recent phase II clinical trial of cilengitide as a second-
line treatment for patients with advanced lung cancer found that at a dose of 600 mg/m2,
median progression free survival was similar to that of patients treated with the current 
standard of care, docetaxel.218 Importantly, in this limited phase II clinical trial, cilengitide 
was associated with fewer grade 3/4 treatment-related adverse events as compared to 
docetaxel.218 These findings suggest that integrin targeting may be an efficacious and 
potentially safe treatment for cancer patients. Interestingly, a function-blocking antibody 
to the integrin α6 subunit has also been developed, and treatment with this antibody was 
able to halt the progression of osteolytic metastases in a xenograft model of metastatic 
prostate cancer.219  
While targeting the α6β4 integrin may be difficult due to the necessity of this 
integrin for integrity of the epithelial-mesenchymal junction, it may be possible to target 
the cytoplasmic signaling domain of the integrin β4 subunit in order to prevent invasive 
and proliferative signaling.77 Notably, mice carrying a targeted deletion of the β4 
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cytoplasmic signaling domain develop smaller and less vascularized tumors than wild-
type controls upon subcutaneous tumor implantation.5 This targeted deletion has also 
been introduced into a mouse model of mammary carcinoma (MMTV-Neu), where mice 
with the targeted deletion exhibit impaired tumor growth and metastases compared to 
controls.27 It has been suggested that targeting of the integrin α6β4 could lead to severe 
adverse effects such as skin and mucosal blistering. However, in normal epithelial 
tissues, the integrin β4 is present only at the basal aspect of cells where they are bound 
to the extracellular matrix, thus protecting this integrin from targeted therapies in normal 
cells. However, during carcinoma progression, the integrin β4 is released from 
hemidesmosomes and relocalized over the entire cell surface where it can be more 
easily targeted.  This change in integrin localization and binding may make it possible to 
preferentially target integrin β4 in malignant cells. Targeting could be accomplished 
using monoclonal antibodies, small molecule inhibitors, or through nanoparticle delivery 
systems that recognize and bind to the integrin β4. 
Where does the integrin β4 fit in with molecular subtypes of TNBC? 
As was previously described, the major molecular classification scheme for 
breast cancer divides tumors into Luminal A, Luminal B, HER2 enriched, and basal-like. 
Additional subtypes including claudin-low and normal-like have also been described.220
In addition to these classification schemes, the Pietenpol group has developed a 
molecular classification scheme specifically for TNBC.221 This classification includes the 
following subtypes: basal-like 1, basal-like 2, immunomodulatory, mesenchymal, 
mesenchymal stem-like, and luminal androgen receptor.221 As these TNBC subtypes 
demonstrate unique chemosensitivity pattens and clinical outcomes, we would like to 
determine which of these specific subtypes display integrin β4 overexpession. This will
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help further delineate the role of integrin β4 in specific subtypes of breast cancer, and 
will allow for further mechanistic studies within specific molecular subtypes.  
What is the role of the integrin β4 in the cancer stem cell population?
In benign epithelia, integrin β4 is expressed in basal progenitor cells. For 
example, integrin β4 expression is strong in the basal cells of stratified squamous 
epithelium222 and in the basal cell layer of bronchial epithelium (Chapter 3). The binding 
partner for the integrin β4 subunit is the integrin α6 subunit (CD49f), a known mediator of 
stem-cell like properties in breast cancer.223 However, the role of integrin β4 in cancer 
stem cells remains unclear. I have shown that integrin β4 expression correlates with the 
expression of stem-cell markers such as CD44, and furthermore, we have demonstrated
that integrin β4 is upregulated in the glioblastoma cancer stem-cell population 
(unpublished data). In breast cancer, expression of the integrin β4 is highly correlated 
with expression of FOXC1, a transcription factor implicated in cancer stem-cell 
development. Further investigations will be needed to clarify the role of the integrin β4 in 
the cancer stem cell population.  
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